Review

Current State of Molecular and Serological Methods for Detection of Porcine Epidemic Diarrhea Virus

Monika Olech

Department of Pathology, National Veterinary Research Institute, 24-100 Puławy, Poland; monika.olech@piwet.pulawy.pl

Abstract: Porcine epidemic diarrhea virus (PEDV), a member of the Coronaviridae family, is the etiological agent of an acute and devastating enteric disease that causes moderate-to-high mortality in suckling piglets. The accurate and early detection of PEDV infection is essential for the prevention and control of the spread of the disease. Many molecular assays have been developed for the detection of PEDV, including reverse-transcription polymerase chain reaction (RT-PCR), real-time RT-PCR (qRT-PCR) and loop-mediated isothermal amplification assays. Additionally, several serological methods have been developed and are widely used for the detection of antibodies against PEDV. Some of them, such as the immunochromatography assay, can generate results very quickly and in field conditions. Molecular assays detect viral RNA in clinical samples rapidly, and with high sensitivity and specificity. Serological assays can determine prior immune exposure to PEDV, can be used to monitor the efficacy of vaccination strategies and may help to predict the duration of immunity in piglets. However, they are less sensitive than nucleic acid-based detection methods. Sanger and next-generation sequencing (NGS) allow the analysis of PEDV cDNA or RNA sequences, and thus, provide highly specific results. Furthermore, NGS based on nonspecific DNA cleavage in clustered regularly interspaced short palindromic repeats (CRISPR)–Cas systems promise major advances in the diagnosis of PEDV infection. The objective of this paper was to summarize the current serological and molecular PEDV assays, highlight their diagnostic performance and emphasize the advantages and drawbacks of the application of individual tests.

Keywords: porcine epidemic diarrhea virus; PEDV; molecular diagnostics; serological diagnostics

1. Introduction

Porcine epidemic diarrhea virus (PEDV) is an alphacoronavirus belonging to the Coronaviridae family and Orthocoronavirinae subfamily; it replicates in enterocytes of the small intestine and causes enteric disease in pigs, with clinical signs of vomiting, anorexia, diarrhea and dehydration [1]. All age groups of pigs are susceptible to porcine epidemic diarrhea; however, the highest mortality occurs in suckling piglets <10 days old and may reach 100%. In older pigs, the virus causes milder disease symptoms and lower mortality rates [2]. This coronavirus was first discovered in the UK and Belgium in the early 1970s [3]. Afterward, PEDV rapidly spread to many countries of the world, including those of Asia and North America, where it has established itself endemically and causes sporadic outbreaks of varying severity [4].

This pathogen is one of the largest RNA viruses, and like other coronaviruses, has a single-stranded, positive-sense RNA genome (excluding polyA) of about 280,000 bp with a 5′ cap and a 3′ polyadenylated tail. The genome of PEDV comprises 5′ and 3′ untranslated regions and seven open reading frames (ORFs), which are ORF1a, ORF1b and ORFs 2–6. The ORFs encode four structural proteins—the glycosylated spike protein (S), the glycosylated membrane protein (M), the envelope protein (E) and the RNA-binding nucleocapsid protein (N)—and three nonstructural polyproteins required for transcription and translation—ORF1a, ORF1b and ORF3 (Figure 1) [5].
Pathogens 2022, 11, 1074

Figure 1. Schematic organization of PEDV genome. The genome encodes open reading frames 1a (ORF1a) and 1b (ORF1b), followed by the genes encoding spike protein (S), accessory protein 3 (ORF3), envelope protein (E), and membrane (M) and nucleocapsid (N) proteins. The genome contains untranslated regions (UTRs) at both the 5′ and 3′ termini. A poly(A) tail is present at the 3′ terminus and a 7-methyl-guanosine cap structure is present at the 5′ end.

The M protein is a part of the viral envelope which plays an important role in the assembly of the virus and the release of viral particles. The M protein can induce the generation of neutralizing anti-M antibodies in the presence of the complement and stimulate the expression of interferon alpha genes [6]. The N protein is involved in viral replication and transcription and binds to the viral RNA forming complex that serves as the core of PEDV. The E protein is vital to viral assembly and budding. Lastly, the S protein is an envelope glycoprotein with a molecular weight of approximately 180 kDa and contains the N terminal S1 region of amino acid (aa) residues 1–735 and the C terminal S2 region of aa residues 736–1383. The S1 region can be divided into five subdomains—S10, S1A, S1B, S1C and S1D—and is involved in virus–receptor recognition and binding, while the S2 region forms the transmembrane structure of the S protein and mediates cell membrane fusion. Furthermore, the whole S protein stimulates the induction of neutralizing antibodies in the host [6,7].

Despite only one PEDV serotype having been described, phylogenetic studies based on the S gene indicated that PEDV can be divided into two main groups, these being genogroups 1 (G1) and 2 (G2), which can be further divided into subgroups. The G1 genogroup comprises the classical strains, including the prototype PEDV strains found in the earliest research in Europe and Belgium (the CV777 strain) and cell culture-adapted vaccine strains obtained via successive in vitro passaging. The G2 genogroup includes global field isolates prevalent around the world which feature typical insertions and deletions in the S gene compared to the G1 PEDV strains. This may be the reason why the currently available commercial vaccines based on the attenuated CV777 strain failed to provide effective protection against epidemic G2 PEDV strains [5,8–10]. Strains of the G1 genogroup present low-to-moderate virulence while strains of the G2 group show higher infectivity and virulence [11].

Outbreaks of severe watery diarrhea with high morbidity and mortality in young piglets are usually the first signs indicating the circulation of PEDV in a herd. A diagnosis of PEDV infection cannot be made without molecular and/or immunological methods because the clinical signs and histopathological lesions associated with PEDV are similar to those caused by other porcine enteric coronaviruses, including porcine deltacoronavirus (PDCoV) or transmissible gastroenteritis virus (TGEV) [1]. Many methods have been developed for the detection of PEDV and have been reported in numerous studies. The objective of this paper was to summarize the currently available serological and molecular assays for the diagnosis of PEDV, to highlight their diagnostic performance and to emphasize the advantages and drawbacks of the application of individual tests.

2. Literature Search Strategy

Literature related to the topic was selected by searching on the PubMed and Google Scholar electronic databases. The following keywords were used to search the published articles: PEDV, ELISA, epitope, M, N, S, fluorescent microsphere immunoassay, FMIA, virus.
neutralization assay, VN, indirect immunofluorescence assay, IFA, immunochromatography assay, IC, lateral flow, RT-PCR, real-time PCR, qRT-PCR, loop-mediated isothermal amplification assays, LAMP, CRISPR, NGS, TaqMan, Sybr Green and sequence. The keywords were used in combinations.

3. Serological Methods for PEDV Detection
3.1. Enzyme-Linked Immunosorbent Assay for the Detection of Antibodies against PEDV

Several commercial and in-house PEDV enzyme-linked immunosorbent assays (ELISAs) have been developed for the detection of immunoglobulin G or mucosal immunoglobulin A in serum, milk, colostrum samples, oral fluid and meat juice. Two variants of such assays are used for the detection of anti-PEDV antibodies: indirect ELISA and competitive or blocking ELISA. In the indirect assay, the antigen is coated onto the surface of the microplate well and incubated with serum samples to facilitate the formation of an antibody–antigen complex. The primary antibody is then allowed to react with the enzyme-labeled secondary antibody; following this, color develops (Figure 2).

![Schematic presentation of two types of ELISA used for detection of anti-PEDV antibodies.](image)

Figure 2. Schematic presentation of two types of ELISA used for detection of anti-PEDV antibodies.

Early indirect ELISAs were based on whole-virus preparations derived from Vero cells [12]. The advantage of assays using whole viral antigens is that whole-virus proteins are expressed, which increases the sensitivity of such tests and simplifies their production. On the other hand, such ELISAs may detect nonspecific background signals and cross-react with other viral antibodies, which consequently reduces their specificity [12]. More recently, indirect ELISAs have used recombinantly expressed and purified structural proteins of PEDV. The antigens used in most of the ELISAs developed so far have been expressed using prokaryotic vectors for protein expression. Although this system achieves high protein yields, it does not offer proper protein folding, which may reduce the diagnostic sensitivity and specificity of ELISAs which depend on such proteins. The precise folding and complex and appropriate post-translational modification of antigens are very important for serological assay development. Therefore, the mammalian protein expression system has recently been used for producing PEDV proteins with proper conformational structures and activity [13–15]. In blocking and competitive ELISAs for PEDV detection, antibodies present in the serum compete with specific polyclonal or monoclonal antibodies, blocking their binding to antigens immobilized in the wells. In these assays, the signal is thus inversely proportional to the number of antibodies in the sample (Figure 2). These ELISAs have been confirmed to be more specific than indirect assays [13,16–18].

ELISAs for the detection of antibodies against PEDV are mainly based on the major structural proteins (S, M, N and E) as antigens. The commercially available ELISAs predominantly use the nucleocapsid protein because it is the most abundantly expressed protein and induces a strong humoral response. Additionally, the N protein is highly conserved in different PEDV strains and is produced most intensively during the early stages of infection, rendering it the most appropriate antigen for early PEDV diagnosis [19,20]. The expression of the N protein in the E. coli expression system was also discovered to be higher than the expression of the S protein [21]. However, some studies revealed that the N and M proteins, as well as the whole virus, cross-reacted with other porcine coronaviruses such as
TGEV and porcine respiratory coronavirus [22,23]. To solve this issue, some researchers have developed immunoassays with truncated PEDV N and M proteins [23]. The epitopes within the PEDV N protein have not been well studied or characterized, although it is known that the N protein does not contain any neutralizing epitopes. To date, only two epitopes (NEP-D4 and NEP-D6) on the N protein have been identified and characterized. Using these antigens in assays, no cross-reaction between PEDV and TGEV was observed, suggesting that they could be utilized to develop precise diagnostic assays for the detection of PEDV [20].

The immunogenicity of the S protein is markedly higher than that of the N protein, and thus, spike-based ELISAs are more sensitive and specific than nucleocapsid-based ones [13,14,16,21,22,24,25]. Moreover, antibodies against the S protein are detectable in serum samples over a longer period than antibodies against the N protein. In contrast to the N protein, the S protein contains multiple neutralizing epitopes capable of inducing neutralizing antibody production; therefore, it is a good candidate for the detection of such antibodies [13]. The spike protein is considered to be the most antigenic PEDV protein. Many neutralizing epitopes on the PEDV S protein have been identified, including COE (aa residues 499–638) [26], S1D (aa residues 636–789) [27] and 2C10 (aa residues 1368–1374) [28]. The S10, S1A and S1B subregions and the 1368GPRLQPY1374 peptide motif found on the carboxy terminal of the spike protein were also suggested to have neutralizing epitopes [14,28,29]. Most recently, additional B cell epitopes, namely 592TSLLASTIDLFYGYP607 [30], SE16 (722SSTFNSTREL731) [31], SS2 (748YSNIGVCK755) and SS6 (764LQDGQVK1771) [30], have been identified as linear epitopes which could be used for developing methods to detect PEDV. Most of the neutralizing epitopes are located in the S1 region; therefore, this region is the main target for the construction of unique PEDV diagnostic methods [7,14]. However, the high molecular weight of the full-length S protein containing both S1 and S2 epitopes presents a major technical challenge for large-scale recombinant protein expression and production. Therefore, many researchers have preferred to use only the S1 protein instead of the full-length S glycoprotein [14,15,32]. Moreover, as was shown by Chang et al., an S1-based ELISA had even higher sensitivity and specificity than an ELISA based on the full-length S protein [15]. The only limitation to the use of this subregion is that it has a particularly high degree of genetic diversity compared to the full-length S protein, which itself is diverse. Therefore, using S1-based ELISA tests, an antibody response may not always be detectable against all circulating PEDV strains.

The PEDV M protein is a structural membrane glycoprotein localized to the virus surface and is the most abundant component of the viral envelope. Thus far, one linear B-cell epitope, 195WAFYVR200, has been screened by hybridoma technology. As was shown, this epitope (designated M-14) was conserved across different PEDV strains and did not cross-react with sera positive for TGEV; thus, it could be used to differentiate PEDV-positive sera from TGEV-positive sera [33]. However, achieving the expression of the full-length M protein is complex and challenging due to many unknown factors, including its sprout function, which can lead to the damage of cell wall structures. The low level of expression of the M protein which is possible limits its potential for use as a diagnostic antigen for application in ELISAs [33]. The E protein is also a diagnostic marker, and this characteristic will be helpful in the development of novel serological assays, as well as in the design of vaccines. The study performed by Lei et al. revealed that besides S1, the recombinant ORF3C and E proteins may also be used as antigens for the detection of anti-PEDV antibodies; however, the S1 protein demonstrated the highest sensitivity [34]. The reactivity of nonstructural protein 1 (Nsp1), Nsp2, the ADP-ribose-1″-monophosphatase domain of Nsp3 and the acidic domain of Nsp3 was less pronounced, indicating that they should be excluded from consideration as novel diagnostic antigens [34].

All the aforementioned methods utilize conventional PEDV-specific polyclonal or monoclonal antibodies which exhibit high levels of instability. This may reduce production yields, and a further disadvantage of these antibodies is their high cost [35]. Single-domain antibodies (sdAbs), called nanobodies, are the smallest antibodies possessing antigen-
binding activity and they have been used to overcome these problems. Due to the lack of light chains, nanobodies exhibit favorable features which traditional antibodies lack, such as thermal stability, permeability, high binding affinity and ease of production in prokaryotic and mammalian expression systems. Recently, biotinylated nanobodies against the PEDV N protein (Nb2) have been used to develop a blocking ELISA for the detection of antibodies against PEDV. This newly developed test showed 93.18% specificity and 100% sensitivity [36]. Another indication of nanobody suitability came in the use of a truncated PEDV S protein spanning aa residues from 444 to 770 and containing most neutralizing epitopes, which was used as an antigen to select S protein-specific sdAbs. The results suggested a potential application of the single-domain antibody named S7, the specificity of which has been confirmed using ELISA and immunocytochemistry. However, S7 did not neutralize PEDV at all, suggesting that this antibody is not suitable for vaccine development [37]. Although the use of nanobodies has many advantages, their generation is quite complicated because it requires the screening of functional antibodies via the immunization of camels, the construction of libraries and phage display [36].

As an example of recent innovation, an amplified luminescent proximity homogenous assay (AlphaLISA) for the detection of antibodies against PEDV has been developed. This bead-based assay platform, originally developed by PerkinElmer, operates via donor and acceptor beads being coupled to antibodies or proteins which interact with the target analyte, bringing the beads into the proximity of each other and leading to energy transfer and the emission of a chemiluminescent signal. The AlphaLISA method allows the detection and characterization of pathogen-specific antibodies with greater speed, sensitivity and simplicity of use [38]. Additionally, an ELISA-like multiplex planar immunoassay (the AgroDiaG PorCoV) has been developed, which has PEDV-specific recombinant S1 proteins printed in an array of spots at the bottom of a microplate for the simultaneous detection and differential diagnosis of PEDV, TGEV and PDCoV in a single sample. The technology and working principle are similar to those of the solid-phase standard ELISA. The reaction is visualized as blue spots, with intensity correlating with the levels of antibodies specific to the viral antigen target in the array. The overall diagnostic sensitivity was 92% for PEDV, 100% for TGEV and 98% for PDCoV; while the diagnostic and analytical specificity for each antigen target was 100%, demonstrating that this assay is an efficient and reliable test for the differential detection and serodiagnosis of PEDV, TGEV and PDCoV [39].

3.2. Fluorescent Microsphere Immunoassay

The fluorescent microsphere immunoassay (FMIA) is a relatively new serodiagnostic tool for the sensitive, specific, rapid and simultaneous detection of antibodies against multiple pathogens. The FMIA utilizes multiple color-coded beads (fluorescent microspheres) whereby each bead can be conjugated to a different antigen that binds to an antibody in biological samples [40]. This assay is based upon xMAP technology, which uses different bead sets internally dyed with different fluorescent preparations. In an FMIA, similarly to capture ELISAs, a capture antigen is covalently attached to a bead surface and binds to a target antibody present in the sample. Antigen-conjugated microsphere–antibody complexes are analyzed using dual-laser instruments and the results are shown as the median fluorescent intensity (Figure 3). Compared to other methods, the FMIA has many advantages. It is more sensitive and specific than an ELISA and can simultaneously detect antibodies against multiple pathogens (up to 500) in a single tested sample. Beads with immobilized PEDV-specific antigens can be used with beads specific for other swine pathogens, including swine influenza virus, porcine reproductive and respiratory syndrome virus, TGEV and other pathogens, for the detection of antibodies against all of them in one assay. The fluorescent microsphere immunoassay is a rapid multiplexing platform and can therefore be applied in large-scale testing. Additionally, FMIA is less labor-intensive than most other methods and requires only a small sample volume for analysis, which is important when the number of clinical samples is limited [4]. Despite these merits, the FMIA is a rarely used method to detect PEDV infection, notwithstanding that in 2015,
an FMIA based on the nucleocapsid protein of PEDV was developed for the detection of PEDV antibodies in serum samples. The specificity and sensitivity of this test were 99.2% and 98.2%, respectively, and the results yielded by this assay correlated strongly with those given by ELISAs and indirect immunofluorescence assays (kappa scores >0.91) [16].

**Figure 3.** Scheme of a microsphere immunoassay (FMIA) based on Luminex® xMAP® technology. Luminex® assays use a set of fluorescent beads where each bead falls in a unique spot on the fluorescent spectrum. The beads are coated with a capture antibody targeted to the analyte of interest. Source: [https://www.sigmaaldrich.com/PL/pl/technical-documents/product-supporting/multiplex/multiplexing-in-vet-med-and-animal-health-research](https://www.sigmaaldrich.com/PL/pl/technical-documents/product-supporting/multiplex/multiplexing-in-vet-med-and-animal-health-research).

### 3.3. Virus Neutralization and Indirect Immunofluorescence Assays

The virus neutralization assay (VN) was previously the most widely employed serological assay for the detection of anti-PEDV-specific antibodies because of its high specificity, which makes the detection of PEDV-neutralizing antibodies possible as early as 7 days post-infection (dpi) [41]. Such antibodies block viral replication, neutralizing or reducing virus infectivity. Originally, the assay which was used to detect neutralizing antibodies against PEDV was a VN assay based on the cytopathic effect (CPE) [24]. However, a VN assay is time-consuming because of the biological processes involved, namely that the test needs to wait until a viral CPE is fully developed; it is also expensive, and it requires well-trained technicians since the direct observation of CPE in cell cultures is subjective. Furthermore, the interpretation of results may be complicated because of cytotoxic effects, and misinterpretations may occur, especially at lower serum dilutions. Therefore, the PEDV fluorescent focus neutralization (FFN) assay has been developed for the rapid detection of PEDV-neutralizing antibodies [16]. The FFN assay is a modification of the VN assay in which the cytopathic effect is not interpreted; thus, this assay has a shorter turn-round time [16]. In this assay, plates with Vero cell cultures inoculated with a virus–serum mixture are incubated for 24–48 h, and then, stained with a fluorophore-conjugated antibody against PEDV. The PEDV-specific antibody level in serum can be estimated based on fluorescence intensity. In addition to measuring neutralizing antibody levels in serum, the FFN assay has also been optimized to quantify PEDV-neutralizing antibodies in colostrum and milk to monitor the lactogenic immunity of suckling piglets [16,42]. Besides VNs and FFNs, imaging cytometry is also an appropriate method for the detection of neutralizing antibodies. Imaging cytometry is utilized in the high-throughput virus reduction neutralization test (HTNT) which was developed by Sarmento et al. [43]. This test offers a more objective and semi-automatic approach that excludes human subjectivity from the examination process and shortens the reading time for a 96-well plate to less than 4 min. The HTNT showed excellent sensitivity and specificity, confirming its value as a tool for the detection of neutralizing antibodies [43].

The indirect immunofluorescence assay (IFA) has been commonly used to identify anti-PEDV antibodies in serum samples and to check the immune status of herds to
PEDV [41,42,44,45]. In this method, Vero cell cultures infected with PEDV are usually used as the antigen. Then, the serum samples to be tested are added to the plate. If antibodies against PEDV are present in the serum, they bind to the virus antigens attached to the plate wells; then these antibodies may be detected by adding fluorophore-conjugated anti-swine secondary antibodies and inspecting the wells using a fluorescence microscope [4,41,42]. The IFA has specificity comparable to an FFN assay but lower diagnostic sensitivity. The time required for an IFA is shorter than for an FFN assay and it is easier to implement; however, the results of an IFA do not correspond to the neutralizing antibody response displayed by the FFN test since the IFA detects IgG antibodies [4,5]. Similarly to the VN assay, the IFA is not automated and is subjective with respect to result reading. Moreover, it was shown that while anti-PEDV antibodies are detectable by the IFA assay in the 1–2 weeks following PEDV exposure, the antibody titers drop to levels undetectable in this assay earlier than they do in the FFN assay [4].

3.4. Immunochromatography Assay

An immunochromatography (IC) assay, also known as a lateral flow test, is a point-of-care device which provides qualitative or semi-quantitative information. The IC is a simple-to-use and rapid immunoassay, the result of which can be read within several minutes without professional equipment or qualified personnel. The IC assay is also very stable and is relatively inexpensive to produce. Hence, this method is currently widely used as a screening test to monitor PEDV infection in field conditions [46].

The two most common formats of the lateral flow IC assay are the double-antibody sandwich assay and the competitive assay. The competitive assay is most suitable for the detection of low-molecular-weight analytes such as protein antigens, while the double-antibody sandwich assay is more suited to target analytes such bacterial pathogens and viruses with higher molecular weight [47,48]. Therefore, the IC assay developed for the detection of PEDV antigens in porcine feces is in the double-antibody sandwich format [48,49].

Common labels for lateral IC assays are carbon, liposomes, latex, colloidal carbon and gold nanoparticles, also known as colloidal gold. Depending on their physicochemical characteristics, some labels can generate a direct (visual) signal, while others produce an analytical signal, to read which additional instrumentation is required. Gold nanoparticles are currently the most widely used label in IC assays because they are inexpensive and easy to prepare, have intense color, and can be perceived by the naked eye. However, an IC assay for the detection of a PEDV N protein which utilized colloidal gold was ten times less sensitive than a real-time RT-PCR (rRT-PCR) assay [48]. The sensitivity of the RT-PCR was nevertheless surpassed by a europium (Eu) (III) chelate-based fluorescent IC assay. This assay required an immunofluorescent analyzer to obtain results; therefore, using this assay for quantitative estimation of the PEDV N protein is possible [49,50]. Moreover, a smartphone camera was also used to quantify the results of IC for detecting of PEDV [51].

More recently, a new paper-based lateral flow immunoassay utilizing color-rich latex beads as the label has been developed for the detection of PEDV in swine fecal samples [52]. This assay had high sensitivity of 88.57% and a limit of detection of 103.60 fifty-percent tissue culture infective doses/mL, and cross-reactions with other related swine viruses were not observed, signifying 100% specificity. Furthermore, this assay gave good agreement with RT-PCR results (92.59%) and was more accurate than previously reported fluorescent and colloidal gold–based IC assays [52].

A colloidal gold–based immunochromatographic strip test for the detection of PEDV-specific secretory immunoglobulin A in milk and colostrum has been developed [53]. Secretory immunoglobulin A is locally produced by plasma cells in the intestinal lamina propria and serves as the first line of immune defense in the animal gut. Therefore, this immunochromatographic test strip provides a simple method for monitoring passive lactogenic immunity in piglets [53].

The IC assay generates a result much faster than rRT-PCR, and thus, is a valuable tool for the rapid diagnosis of PEDV infection in pigs. The disadvantage of the test
is that the interpretation of weak bands in the results may sometimes be problematic because the results are generally read with the naked eye. Therefore, it is important to minimize nonspecific bands in the test line. If the density of antibodies is too high, it can lead to nonspecific binding and a lack of specificity. Consequently, each test must be validated regarding the optimal density of antibodies which will minimize the occurrence of nonspecific bands. An additional possible drawback is that most IC assays are not quantitative and are not suitable for large-scale screening [48].

4. Methods for the Detection of PEDV Genome and/or Antigens

4.1. Antigen ELISA

Many quick and highly specific assays have been established for the detection of PEDV antibodies, but these antibodies can only be detected between 6 and 14 dpi, which may delay the diagnosis of PEDV [16]. Serological assays showing the presence of antibodies against PEDV are used to determine whether a pig has previously been exposed to the virus, and these assays can be used to monitor the efficacy of vaccination strategies. However, more actionable knowledge of a given epizootiological situation which is dynamic proceeds from the results of attempts to detect a virus genome that is currently infecting pigs. Fecal shedding of PEDV occurs as soon as 1–3 dpi, and PEDV RNA may be detected in fecal samples after 30 dpi [41]. Sandwich or capture ELISA assays for the earliest detection of individual PEDV antigens in fecal samples have been established [35,54–58]. The adoption of the sandwich format overcomes most issues associated with cross-reactivity as it employs two antibodies, each specific to a different epitope region. In such ELISAs, the wells are coated with capture antibodies specific to the S, M or N PEDV proteins, and after incubation with the sample, virus antigens bind to the capture antibody. The reaction is developed by adding an enzyme-conjugated secondary antibody which reacts with an appropriate substrate. Coloration signifies a positive result, while a lack of coloration indicates a negative one. The use of fecal samples has some advantages over the use of blood samples, including easy and non-invasive collection. On the other hand, the drawbacks include low virus concentrations and occurrences of nonspecific reactions that may reduce the sensitivity and specificity of serological assays. Additionally, fecal samples do not have constant usefulness over the course of porcine epidemic diarrhea; fecal shedding was consistently detected during the acute phase of PEDV infection but less frequently detected during the incubation and recovery periods. Therefore, the samples should be collected immediately after the appearance of clinical symptoms [55].

4.2. RT-PCR and qPCR

PCR constitutes one of the greatest advances in molecular biology. A practical advantage of PCR-based methods is the possibility to test different biological samples, such as rectal swabs, feces, oral fluid and intestinal samples, maintaining reasonable sensitivity and specificity across them all [4,59–61]. The chain reaction utilizes multiple stepwise temperature cycles and a thermostable DNA polymerase to amplify a specific DNA fragment; therefore, for the detection of viral RNA, a preliminary step is required in which a reverse transcriptase enzyme is used to convert RNA to cDNA. Several one-step or nested reverse-transcription PCR assays have been developed for the detection of PEDV and are described in the literature [19,62–69] (Table 1).
Table 1. Summary of RT-PCR assays for PEDV diagnosis.

| PCR Type       | Primer Name          | Primer Sequences (5′-3′)                                                                 | Target Region (Size) | Limit of Detection          | Ref. |
|----------------|----------------------|------------------------------------------------------------------------------------------|----------------------|------------------------------|------|
| RT-PCR         | PEDV M-F             | ACACCTATAGGGGCGCCTGTA                                                                  | M (854 bp)           | 100 TCID_50/sample          | [62] |
|                | PEDV M-R             | AACCCTAAGGGGCGCATAGA                                                                   |                      |                              |      |
| RT-nested PCR  | PEDV/N-F             | TTGGCATTITCCTACTCTCTCCGA                                                                 | N (1327 bp)          | Not defined                  | [63] |
|                | PEDV/N-R             | AGATGAAAAAGTACTGCGTCTCC                                                                 | N (540 bp)           |                              |      |
|                | PEDV/N-F2            | AGGAACGTCGCCCTCAAAGACATCCCC                                                            |                      |                              |      |
|                | PEDV/N-R2            | CCAAGTAAAGCCGTCTAAACATTTG                                                               |                      |                              |      |
| RT-PCR         | PEDV Fwd             | ACAAAGTCTGTAACCACTGCC                                                                  | N (691 bp)           | Not defined                  | [64] |
|                | PEDV Rev             |                                                                                         |                      |                              |      |
| RT-PCR         | PEDV P1              | GACACATTTTGTCATGTC                                                                     | M (377 bp)           | 10^4 TCID_50/mL              | [65] |
|                | PEDV P2              | GTTATAGCTAATAAGAGCCTTCC                                                                 |                      |                              |      |
| RT-PCR         | PEDV E1              | TAGACAAGCTTCAAATGTGAC                                                                  | OFR3 (264 bp for field strains and 215 for attenuated strains) | 6.10 × 10^4 - 7.30 copies/µL × 10^5 | [66] |
|                | PEDV E2              | GTATAAAGGATAAAAGAGGCC                                                                 |                      |                              |      |
| RT-PCR         | F1-V                 | CCAGGTGCTACTCAACTCTGTTAGTCG                                                            | S (442 bp for variant PEDV) | 5 × 10^5 DNA copies/reaction | [67] |
|                | R1                   | TCAATTCCCATGAATGCGG                                                                     |                      |                              |      |
| RT-PCR         | F1-C                 | TCTCAGTTACATGATTCTGCC                                                                  | S (270 bp for classical PEDV) | 5 × 10^5 DNA copies/reaction | [67] |
|                | R1                   | TCAATTCCCATGAATGCGG                                                                     |                      |                              |      |
| RT-PCR         | PEDV F               | TTTATTCGTACGCCC                                                                       | S1 (197 bp)          | Not defined                  | [68] |
|                | PEDV R               | AGATTTACAACACCATTTG                                                                   |                      |                              |      |
| RT-PCR         | PEDV F               | GGTCTTATCCCGTGGAGGT                                                                   | M (170 bp)           | Not defined                  | [69] |
|                | PEDV R               | AACACCAAGGCCAAAGATCTCGT                                                                  |                      |                              |      |
| Multiplex RT-PCR | PEDV P1              | (TTCGACTCGCAAGCCAGCA)                                                                 | S (651 bp)           | 10^2 TCID_50/mL              | [70] |
| (PEDV/TGEV/GAR)| PEDV P2              | (TTCGACTCGCAAGCCAGCA)                                                                 |                      |                              |      |
|                | TGEV T1              | GTGTTTTTGGTYRAAAATGC                                                                  | S (859 bp)           | 10^1 TCID_50/mL              | [70] |
|                | TGEV T2              | CACTAACAAAGTGAGGCA                                                                    |                      |                              |      |
| Multiplex RT-PCR | GAR rot3             | AAAGATGCTAGGGACAAAATTG                                                                | Segment 6 region (309 bp) | 10^3 TCID_50/mL              | [70] |
| (PCV2/TGEV/PEDV/GAR)| GAR rot 5          | TTCAGATGTGGACGTATCTCC                                                                  |                      |                              |      |
| Multiplex RT-PCR | PCV2-F               | CCGATATTTGATAGCTGTCG                                                                    | ORF2 (481 bp)        | 2.17 × 10^3/reaction        | [71] |
| (PCV2/TGEV/PEDV/GAR)| PCV2-R               | ACCTGTCAGCCTACGTCG                                                                     |                      |                              |      |
|                | TGEV-F               | GTGGTTTTTGGTYRAAAATGC                                                                  | S (859 bp)           | 1.74 × 10^4/reaction        | [71] |
|                | TGEV-R               | ACTAACAAAGTGAGGCA                                                                    |                      |                              |      |
| Multiplex RT-PCR | PEDV-F               | TCTCAGTTACAGCAACCAGCC                                                                  | S (651 bp)           | 2.1 × 10^3/reaction         | [71] |
| (PCV2/TGEV/PEDV/GAR)| PEDV-R               | CATATGCAAGCTGACGTA                                                                    |                      |                              |      |
| Multiplex RT-PCR | GAR-F               | AAAGATGCTAGGGCACCAGGACC                                                                | Segment 6 region (309 bp) | 1.26 × 10^4/reaction        | [71] |
| (PCV2/TGEV/PEDV/GAR)| GAR-R               | TTCAGATGTGGACGTATCTCC                                                                  |                      |                              |      |
| PCR Type | Primer Name | Primer Sequences (5'-3') | Target Region (Size) | Limit of Detection | Ref. |
|----------|-------------|--------------------------|----------------------|-------------------|-----|
| Multiplex RT-PCR (PEDV/TGEV/PRV-A/PSaV/PKoV/PDCoV) | PEDV-F | TGGGACCTGCTACTGAGGGTGTT | N (600 bp) | 1 ng cDNA | [72] |
| | PEDV-R | TTATTTGCGCTTTGAGGAATT | | | |
| | PKoV-F | GGGCAATGACATTACAGCCGG | Polypeptide (998 bp) | 10 ng cDNA | |
| | PKoV-R | AGCTGCTAGGAGCTCTGCAAG | | | |
| | TGEV-F | CCGAAGCAAGGAGAGCTCCTTAC | N (820 bp) | 1 ng cDNA | |
| | TGEV-R | GCACCTGTTTGGGAATTCAAGT | | | |
| | PDCoV-F | CACTGTTTGGGAATTCAAGT | N (497 bp) | 1 ng cDNA | |
| | PDCoV-R | AGCTGCTAGGAGCTCTGCAAG | | | |
| | PRV-A-F | GTATGTTATGGAATATACCC | VP7 (350 bp) | 10 ng cDNA | |
| | PRV-A-R | TGATGTTATGGAATATACCC | | | |
| | PSaV-F | TAGCAACATGAGGAC | Polyprotein (194 bp) | 1 ng cDNA | |
| | PSaV-R | ATGACACTGGTGAACGGCAT | | | |
| | Multiplex RT-PCR (PRRSV/PEDV/CSFV/TGEV) | PEDV M-F | GGTGTCAGATGCTATTGCAC | M (435 bp) | 1 × 10^3 copies/µL | |
| | PEDV M-R | TGAAGACCATTGAGCAACAG | | | |
| | CSFV 5'UTR-F | GCCCTGTTGAGGCTCTAAGTCC | 5'UTR (116 bp) | 1 × 10^3 copies/µL | [73] |
| | CSFV 5'UTR-R | GGGTAAAGCTGTTCGTCTC | | | |
| | PRRSV M-F | ACCGTCAAGATGGTTTGTG | M (197 bp) | 1 × 10^3 copies/µL | |
| | PRRSV M-R | GCTTTGCTGCCACCAACAC | | | |
| | TGEV N-F | GACAAACTGGATGATGACTCTG | M (450 bp) | 27.2 µg/µL RNA | |
| | TGEV N-R | AGTGGTATTTGGTTTGACTAGT | M (291 bp) | | |
| | Multiplex nested RT-PCR (PEDV/TGEV/PRV-A) | PEDV M1-F | GAAATTGACATTGATAATATGGAATTCCAG GAAATTGACATTGATAATATGGAATTCCAG | M (450 bp) | 10^2 TCID_{50}/mL | [74] |
| | PEDV M2-F | TGAAGACCATTGAGCAACAG | M (291 bp) | | |
| | PEDV M3-F | TGCTGCTAGATGCTATTGCAC | | | |
| | PEDV M4-F | GCCCTGTTGAGGCTCTAAGTCC | | | |
| | TGEV S1 | AGGGTAAAGGCTATTGACTG | S (950 bp) | | |
| | TGEV S2 | GGTGTAAGCTGTTCGTCTC | S (962 bp) | | |
| | TGEV S3 | GGGTAAAGGCTATTGACTG | | | |
| | TGEV S4 | GGTGTAAGCTGTTCGTCTC | | | |
| | PRV-A P1 | GCGCTTTGGAATGGCTACAGTGAATGCTCT | NSP5 (317 bp) | 10^3 TCID_{50}/mL | |
| | PRV-A P2 | GCCACATGCTGTTGATTGCATAG | NSP5 (208 bp) | | |
| | PRV-A P3 | CTCAAGATGGCTAGAAGCTTCTCC | | | |
| | PRV-A P4 | TGAGAGCTACATTGCTTAAGCAGATCAGA | | | |
| | One-step triplex RT-PCR (PEDV/PSV/PSaV) | PEDV-F | CTGGAGCCATGATGCTTCCGACAG | SI (659 pb) | 10^4 copies/µL | [75] |
| | PEDV-R | GGAATTTGACATTGATAATATGGAATTCCAG | | | |
| | PSV-F | TGGTCAGAGGACTGAGAG | Conserved region (428 bp) | 10^4 copies/µL | |
| | PSV-R | GCCCTGTTGACCAATCTGCTTCC | | | |
| | SaV-F | TCCAGCGAGGCTTGCACACAG | VP1 (246 bp) | 10^4 copies/µL | |
| | SaV-R | CAGGCCACATGCTGCTTCCCGACAG | | | |
### Table 1. Cont.

| PCR Type                        | Primer Name         | Primer Sequences (5′-3′)       | Target Region (Size) | Limit of Detection | Ref. |
|---------------------------------|---------------------|--------------------------------|----------------------|--------------------|------|
| **Duplex RT-PCR (TGEV/PEDV)**   | PEDV T1             | GTGGTTTTGGTYRTIAAAATGC         | S (651 bp)           | 10^3 TCID_{50}/mL  | [76] |
|                                 | PEDV T2             | CACTAACCAACCGCTGAGCTA          |                      |                    |      |
| TGEV P1                         | TGEV P2             | TCTCGAGTCACGAAACGGCA           | S (859 bp)           | 10^2 TCID_{50}/mL  |      |
| **Multiplex RT-PCR (PEDV/TGEV)**| PEDV PA             | GGGCCCGTCTATAGTATTGA           | M (412 bp)           | 10 TCID_{50}/mL    | [77] |
|                                 | PEDV PB             | AGAACACCAAAAGATGTC            |                      |                    |      |
| TGEV TA                         | TGEV TB             | GATGCCGACCAGATAGAAGT           | N (612 bp)           | 10 TCID_{50}/mL    |      |

F—forward; R—reverse; PEDV—porcine epidemic diarrhea virus; TGEV—transmissible gastroenteritis virus; PSV—porcine sapelovirus; PsaV—porcine sapovirus; PRV-A—porcine group A rotavirus; PRRSV—porcine respiratory syndrome virus; CSFV—classical swine fever virus; PKoV—porcine kobuvirus; PDCoV—porcine deltacoronavirus; GAR—porcine group A rotavirus; PCV2—porcine circovirus 2; Ref.—reference’ bp—base pair.

### Table 2. Summary of qRT-PCR assays for PEDV diagnosis.

| PCR Type                        | Primer Name         | Primer Sequences (5′-3′)       | Target Region (Size) | Limit of Detection | Ref. |
|---------------------------------|---------------------|--------------------------------|----------------------|--------------------|------|
| **SYBR™ Green one-step qRT-PCR**| mPEDNF              | CGCCAAGAATGCAACCCACTAA         | N (191 bp)           | 0.5 \times 10^{0.01} TCID_{50}/mL for the spiked feces and 10^{0.01} TCID_{50}/mL for spiked jejunum | [78] |
|                                 | PEDV-R              | TTGCCCTCTTGTTGACCATGA          |                      |                    | [79] |
| **Duplex qRT-PCR**              | PEDV S1-F           | AGGCGGTTCTTTCAAAATTTAATG       | S1 (191 bp for virulent PEDV; 179 bp for variant PEDV) | 1 DNA copy/µL   | [80] |
| Virulent PEDV S1-P               | PEDV S1-R           | GAAATGCCAATCTCAAAGCC           |                      |                    |      |
| Variant PEDV S1-P               | PEDV M-F            | CATGCGCTAGCTTTCAAGGCC          | M (181 bp for both virulent and variant PEDVs) | 1 DNA copy/µL   |      |
| PEDV M-R                        | PEDV M-P            | 56-FAM/CATTCTTGCTTGCAGTCCTGA/ZEN |                      |                    | [79] |
| **Multiplex qRT-PCR (PEDV/TGEV)**| PEDV-F              | CGCAAAAACCTGAACCCACTAAATTT    | N (198 bp)           | 1 TCID_{50}/mL    |      |
|                                 | PEDV-R              | TTGCCCTCTTGTTGACCATGA          |                      |                    |      |
|                                 | PED-Cy5-P           | Cy5-TGGTGCATTGCCCAGCTCCTGC-BHQ3 |                      |                    |      |
| **TGEV-F**                      | TGEV-R              | GCAAGTTAAAGGTGATGTCACCA        | N (120 bp)           | 1 TCID_{50}/mL    |      |
| TGEF-EAM-P                      |                      | 6FAM-TGGCCTCTTGAGTTGCAACCGA-BHQ1 |                      |                    |      |
| PCR Type          | Primer Name  | Primer Sequences (5′-3′)                        | Target Region (Size) | Limit of Detection | Ref. |
|------------------|--------------|------------------------------------------------|----------------------|--------------------|------|
| **qRT-PCR**      | PEDV S-F     | ACGTCCCTTTAACGTCAATTACCA                       | S (111 bp)           | 10^{−0.2} TCID\textsubscript{50}/mL | [81] |
|                  | PEDV S-R     | TATACCTGGATCACATCGAGGTCA                       |                      |                    |      |
|                  | PEDV S-P     | FAM-TGAGTGAATCTGGCAGGCCTAACCAC-BHQ            |                      |                    |      |
|                  | PEDV N-F     | GAATTCCAAGGAGCAGAACATCAG                      | N (87 bp)            | 10^{−2.2} TCID\textsubscript{50}/mL |      |
|                  | PEDV N-R     | TTTGTCAGAAATTCGCCATCT                         |                      |                    |      |
|                  | PEDV N-P     | FAM-CGACAGTCTTTCTTCGACCCCA-BHQ                |                      |                    |      |
| **Multiplex qRT-PCR** | F-C          | GTCGTGGTGGTGGTGTTGA                           | S (89 bp for classical PEDV) | 5 × 10^2 DNA copies/reaction | [67] |
|                  | R-C          | CATTGAAAGCCGACATAGT                           |                      |                    |      |
|                  | C-P          | FAM-TAGCTGCACTGTGGCACAGGCATTG-BHQ1            |                      |                    |      |
| **Duplex qRT-PCR (PEDV/PDCoV)** | F-V          | GTGACTGAGGCCGGATATCCTAC                    | S (98 bp for variant PEDV) | 5 × 10^2 DNA copies/reaction |      |
|                  | R-V          | CCATGAGGAGCAGTAGCTAC                        |                      |                    |      |
|                  | V-P          | VIC-TGACTCTGGCAGCAGACCATA-CBH1               |                      |                    |      |
| **Multiplex qRT-PCR (PEDV/PDCoV/SADS-CoV/PToV)** | PEDV-F      | GTTCTTCTTAAATTTGAGTCTG                      | M (79 bp)            | 7 RNA copies/reaction | [82] |
|                  | PEDV-R      | ACCACACTTGAAACCTGATAC                         |                      |                    |      |
|                  | PEDV-P      | FAM-TTACCATACAGGCCGTTATTAAC-GAC-MGB          |                      |                    |      |
| **PDCoV-F**     | PEDV-F      | GGTITGGGCGGAGGAGCA                          | M (105 bp)           | 7 RNA copies/reaction |      |
|                  | PEDV-R      | CGGCCCATACACAGGAATG                          |                      |                    |      |
|                  | PEDV-P      | FAM-CATTCTTG/GLENAGTTCGTA-1ABkFQ             |                      |                    |      |
| **PDCoV-rF**    | PEDV-F      | TGAGATGACCTCCTTCGAGGGA                        | M (105 bp)           | 7 RNA copies/reaction |      |
|                  | PEDV-R      | GAGAATTGGAGCAGATCCG                        |                      |                    |      |
|                  | PEDV-P      | NED-TGGACACAGATCTCCTAGCGCATAA-MGB            |                      |                    |      |
| **Multiplex qRT-PCR (PEDV/PDCoV/SADS-CoV/PToV)** | PEDV-F      | CTCCTTGAATTTGAGTCTG                      | ORF1a (85 bp)        | 1 × 10^2 copies/µL | [83] |
|                  | PEDV-R      | ACCACACTTGAAACCTGATAC                         |                      |                    |      |
|                  | PEDV-P      | FAM-TTACCATACAGGCCGTTATTAAC-GAC-MGB          |                      |                    |      |
| **PDCoV-F**     | PEDV-F      | AAGCCTTTTCAAGGAGCATACT                      | ORF1b (87 bp)        | 1 × 10^2 copies/µL |      |
|                  | PEDV-R      | TACCAGCAATACTCTCTGAAAGGCA                    |                      |                    |      |
|                  | PEDV-P      | Texas Red-TAGATGACCTGACACTGCTTCAG-BHQ2      |                      |                    |      |
| **PDCoV-rF**    | PToV-F      | TCATCCACCAGTCTCAGAT                     | ORF1a (73 bp)        | 1 × 10^2 copies/µL |      |
|                  | PToV-R      | TGACGAAATCTCTGTCCTCAAA            |                      |                    |      |
|                  | PToV-P      | VIC-CCTCAGATTCGAGATAGAACC-BHQ1           |                      |                    |      |
| **PDCoV-F**     | SADS-CoV-F  | CATTTGCCGCTCCATTCAA                      | ORF1a (95 bp)        | 1 × 10^2 copies/µL |      |
|                  | SADS-CoV-R  | AACCAGCAATITTATGCTGAA                      |                      |                    |      |
|                  | SADS-CoV-P  | Cy5-CAAGTCCACAGCTCAACACACC-TACT-BHQ3      |                      |                    |      |
| PCR Type                  | Primer Name                | Primer Sequences (5′-3′)                                                                 | Target Region (Size) | Limit of Detection   | Ref.  |
|--------------------------|----------------------------|-----------------------------------------------------------------------------------------|----------------------|----------------------|-------|
| 5-Plex qRT-PCR           | PEDV-N1195-F               | GAAGAGGCCATCTCAGATGTGT<br>AACAGGCTTGCAGCATTCCAA<br>JUN/TGTGCACTTCTAGTGACTCAAGCCAA/QSY | N (75 bp)            | 8 genomic copies/reaction | [84]  |
|                          | PEDV-N1269-R               |                                                                                         |                      |                      |       |
|                          | PEDV-N1221-P               |                                                                                         |                      |                      |       |
|                          | PDCoV-N-F2                 | CCAGACATGTCCTGGTTCTTT<br>CYCCCTGAAGATGTTCT<br>ABY/ARATGCCTTTCGCAACACCTTG/QSY       | N (68 bp)            | 4 genomic copies/reaction | [84]  |
|                          | PDCoV-N-R2                 |                                                                                         |                      |                      |       |
|                          | PDCoV-N-P                  |                                                                                         |                      |                      |       |
|                          | TGEV-S-F2                  | GTGTTAAATATCTATTTGCCGTCGCTA<br>GCGACACATGTTTTAAGACT<br>VIC/TTGCTATATCTAGTGCGYAGT/MGB | S (101 bp)           | 16 genomic copies/reaction | [84]  |
|                          | TGEV-S-R2                  |                                                                                         |                      |                      |       |
|                          | TGEV-S-P                   |                                                                                         |                      |                      |       |
|                          | SADS-N-F3                  | CCGAGGCTCAGAAGGTGTTAAAA<br>TGTTAAGGAGCAGCGGTTAGG | N (85 bp)            | 6.8 genomic copies/reaction | [84]  |
|                          | SADS-N-R3                  |                                                                                         |                      |                      |       |
|                          | SADS-N-P                   |                                                                                         |                      |                      |       |
| Multiplex qRT-PCR        | PEDV-F                     | GATACTTGGGCTCTTGTGT<br>CACAAAGGATGCTATTGAGCG<br>FAM-TTCAAGCATTGTGGCATT-A/MRA         | M (150 bp)           | 100 copies/reaction  | [85]  |
|                          | PEDV-R                     |                                                                                         |                      |                      |       |
|                          | PEDV-P                     |                                                                                         |                      |                      |       |
|                          | PDCoV-F                    | ATTTTGACCCGATGTGACA<br>GCCAGGATATAAAGGTGAG<br>Cy5-TAAGAAAGGCTACGTTATTTCTGTTG-BHQ2 | M (92 bp)            | 100 copies/reaction  | [85]  |
|                          | PDCoV-R                    |                                                                                         |                      |                      |       |
|                          | PDCoV-P                    |                                                                                         |                      |                      |       |
|                          | TGEV-F                     | TGCCATGAACAAACCAAC<br>GAACGTATCAGAAT<br>HEX-TAGACACGACTACCAAGC-BHQ1                | N (81 bp)            | 100 copies/reaction  |       |
|                          | TGEV-R                     |                                                                                         |                      |                      |       |
|                          | TGEV-P                     |                                                                                         |                      |                      |       |
|                          | PEAV-F                     | TCTCGGTTAATCTAAACC<br>CATCCACATCTCAACCTG<br>TexasRed-AGAAGCTTATACTGATGCGCCCA-BHQ2 | N (150 bp)           | 100 copies/reaction  | [86]  |
|                          | PEAV-R                     |                                                                                         |                      |                      |       |
|                          | PEAV-P                     |                                                                                         |                      |                      |       |
| Duplex SYBR Green qPCR   | PEDV F                     | GAGGGTGTTTTCTGGCTG<br>TGCCCTGTTGTTACTG<br>N (226 bp)                                   | 10 copies/µL         |                      | [86]  |
|                          | PEDV R                     |                                                                                         |                      |                      |       |
|                          | PBoV F                     | GGTGATCCCTGCAATAA<br>TGCAGAAGATGCTAATTAA<br>VPI (131 bp)                                | 10 copies/µL         |                      |       |
|                          | PBoV R                     |                                                                                         |                      |                      |       |
| TaqMan probe-based qPCR  | eU-ORF3 F                  | GCCGAATTCTATGTTCTGGACTTTTC<br>ACGCAGGCTATTCAATTGACATA<br>AGACTTATGTTCTAGCTTT<br>ORF3 (673 bp for virulent strains and 626 bp for vaccine strains) | 37 copies/reaction   |                      | [87]  |
|                          | eU-ORF3 R                  |                                                                                         |                      |                      |       |
|                          | ORF3 R                     |                                                                                         |                      |                      |       |
|                          | ORF3 P                     |                                                                                         |                      |                      |       |
Table 2. Cont.

| PCR Type                        | Primer Name | Primer Sequences (5’-3’) | Target Region (Size) | Limit of Detection | Ref. |
|---------------------------------|-------------|--------------------------|----------------------|--------------------|------|
| SYBR Green I-based duplex qRT-PCR (PEDV/PCV3) | PEDV-F | AAATGGGAAGTCGGCAGA       | ORF1 (163 bp)         | $3.46 \times 10^3$ copies/µL | [88] |
|                                 | PEDV-R     | GTTTGTGTTGCGGTAG         |                      |                    |      |
|                                 | PCV3-F     | CTACGAGTGTTCTGAAGA       | Rep (136 bp)          | $6.12 \times 10^3$ copies/µL |      |
|                                 | PCV3-R     | CCTCACCACCTCCACAATA      |                      |                    |      |
| Multiplex EvaGreen qPCR (TGEV/RVA/RVC/ PEDV/PCV2) | PEDV-F | GCGCGAATCTGAATGAGCAA     | N (110 bp)            | 5 copies/µL        |      |
|                                 | PEDV-R     | CGTGCGGCGTGAGTTCTGTT    |                      |                    |      |
|                                 | TGEV-F     | ATGGTGTAGGTTAGATTITTC    | S (106 bp)            | 5 copies/µL        | [89] |
|                                 | TGEV-R     | AATACAAATCTTTAAGAATTTTCA |                      |                    |      |
|                                 | RVA-F      | TGAAGTGGAGCAGGCTAA       | VP6 (97 bp)           | 5 copies/µL        |      |
|                                 | RVA-R      | ACGAAATTCACACCTTACTTG   |                      |                    |      |
|                                 | RVC-F      | TGTGCATCCGTGAAGAAGATGGT  | VP6 (126 bp)          | 5 copies/µL        |      |
|                                 | RVC-R      | GCATTAGCCCTACGCAAGCC     |                      |                    |      |
|                                 | PCV2-F     | ATCCGAAGTGCGGGAGA        | CP (162 bp)           | 50 copies/µL       |      |
|                                 | PCV2-R     | TGACGTATCCAAAGGAGCG     |                      |                    |      |
| Duplex qRT-PCR                  | F-C/V      | GCTAGTGGCGTTCATGG         | S1 (110 bp)           | $4.8 \times 10^2$ DNA copies/reaction | [68] |
|                                 | R-C/V      | TGTAATATAGGGTGATACACCAC  |                      |                    |      |
|                                 | V-Probe (classical PEDV) | CY5-TACATCGATTCTGGTCAGGGCTTTGAG-BHQ2 | | | |
|                                 | C-Probe (variant PEDV) | FAM-CCATATTAGAGGTGGTCATGGCTTTGAG-BHQ1 | | | |
| qRT-PCR                         | PEDV F | CAGGACACATCTTGGTGCTCTT   | M (240 bp)            | 10 copies/ml       | [69] |
|                                 | PEDV R    | CAAGCAATGCTAATCTAAAGGAGTGT | | | |
|                                 | PEDV P    | FAM-AAGCCTCTCTAC-MGB     |                      |                    |      |

F—forward; R—reverse; P—probe; TGEV—transmissible gastroenteritis virus; GAR—porcine group A rotavirus; PDCoV—porcine deltacoronavirus; SADS-CoV—swine acute diarrhea syndrome coronavirus; PToV—porcine torovirus; PEAV—porcine enteric alphacoronavirus; PBoV—porcine bocavirus; PCV3—porcine circovirus 3; RVA—rotavirus A; RVC—porcine rotavirus C; PCV2—porcine circovirus 2; Ref.—reference; bp—base pair.
Multiplex RT-PCR makes amplification possible of more than one target fragment using more than one specific pair of primers in one reaction tube. Multiplex RT-PCRs are commonly used by veterinary diagnostic laboratories for the differential detection of related multiple pathogens, especially those causing diseases with similar symptoms. Multiplex RT-PCRs have been developed for the differentiation of PEDV from other porcine viruses [70–77] (Table 1). In standard RT-PCRs such as these, the DNA products are visualized by electrophoresis on agarose gel to reveal the presence of expected DNA bands. Using this technique, only semi-quantitative results can be achieved. Furthermore, this method can fail when samples contain low concentrations of DNA.

qRT-PCR assays are currently favored because they are more sensitive, faster and much easier to perform than standard RT-PCRs and can provide quantitative detection. Many qRT-PCR test protocols have been published by researchers around the world for the specific detection of PEDV after satisfactory evaluation of their sensitivity and specificity using clinical samples or samples originating from experimentally infected pigs [67–69,78,89] (Table 2). Some commercial multiplex qRT-PCR assays for the simultaneous detection and differentiation of PDCoV, PEDV and TGEV have been developed (e.g., the VetMAX PEDV/TGEV/SDCoV (PDCoV) Kit from Applied Biosystems). The major advantages of qRT-PCR methods are high sensitivity, throughput and process automation, the quantification of viral loads and the possibility of the simultaneous (multiplexed) identification and discrimination of different swine pathogens. Two real-time PCR methods are the most popular: TaqMan and SYBR Green. The SYBR Green method uses a fluorescent nonspecific DNA-binding dye, while the TaqMan method uses a specially designed probe that is complementary to the internal fragment of the target DNA. Both of them have high sensitivity. The TaqMan-probe method has higher specificity but it is less versatile in its application since one probe is able to detect only one specific fragment of DNA. Although multiplex real-time PCR is a powerful genetic method, the development of an application of this method is sometimes challenging. The presence of multiple primer pairs in multiplex PCR assays may result in the formation of nonspecific products. Therefore, special attention should be paid to designing specific primers and probes [84]. The primer length, melting temperature, different annealing temperatures for different primers, guanine–cytosine content, secondary structure, repeats, 3' end stability, product position and optimization of PCR conditions have to be considered. In particular, the primer pairs should be not complementary to each other. In order to block nonspecific priming, a novel dual-priming oligonucleotide (DPO) system was recently used in multiplex RT-PCR assays for the specific detection of PEDV and other swine viruses, including TGEV, PRV-A, PDCoV and swine acute diarrhea syndrome coronavirus (SADS-CoV) [90,91]. The DPO primers have a special structure which is different from that of conventional primers. They contain two separate sequence fragments linked through a polydeoxyinosine linker, which prevents the formation of primer-dimer and hairpin structures and therefore eliminates nonspecific interactions. Moreover, using the DPO primers, optimization of the annealing temperature is not required since annealing temperatures already differ for the two primer fragments as a function of their structure. This simplifies primer design [90,91]. Because coronaviruses evolve rapidly, the selection of the most suitable pair of primers is a matter of critical importance. The selection process should attempt to specify primers that will be able to detect all circulating variant PEDV strains and that will be able distinguish PEDV from other closely related viruses, such as PDCoV or TGEV. Updated PEDV sequence information is required at the time of the experiment design to ascertain whether the primers and probes designed for the virus sequences available at the time of their formulation are suitable for detection of the new virus strains.

4.3. Loop-Mediated Isothermal Amplification Assay

Recently, a variety of isothermal nucleic acid amplification techniques have been developed to improve conventional PCR methods. Insulated isothermal amplification systems do not offer the ability to multiplex, but might provide the opportunity to deploy tests in the
field in countries where laboratories are not easily accessible. These methods include loopmediated isothermal amplification (LAMP) assays, strand displacement amplification [92], recombinase polymerase amplification (RPA) [93], and cross-priming amplification [94]. A method among these which offers a simple, effective and rapid alternative to classical or real-time PCRs is LAMP. This type of amplification uses four to six primers that recognize six to eight DNA target regions in association with Bst polymerase, which has strand-displacement activity [95]. The method does not require expensive equipment such as a thermocycler; it only requires a water bath or heat block, and the entire procedure can be completed within 60 min. The application of LAMP tests might reduce the cost of detection of coronavirus. Another recommending factor of these assays is that the amount of amplified DNA that they produce is high compared to the standard PCR assays.

A number of LAMP-based detection methods have been developed and applied to the detection of PEDV. The amplified product of these assays can be detected as the precipitation of magnesium pyrophosphate or fluorescent dye and is visible to the naked eye, providing rapid qualitative results. Furthermore, turbidity can also be measured in real time, allowing quantitative analysis of the target DNA. However, fluorescent dye detection methods require additional instruments such as a fluorescence detector, which limits the applicability of reverse-transcription LAMP (RT-LAMP) as a field diagnostic assay [96]. Recently, hydroxynaphthol blue (HNB), a metal colorimetric indicator, was also used for the detection of PEDV [96]. The reduction in Mg2+ concentration in a LAMP solution causes a color change in the HNB solution from purple to sky blue, granting a means of direct visual detection. This method is expected to be useful for routine application in the field. The only drawback of this method may be the difficulty in distinguishing the color change between positive and negative samples when the amount of the template in the tested sample is low [96].

The first RT-LAMP assay to amplify PEDV was developed by Ren and Li and was based on the detection of a fragment of the PEDV N gene [95]. The detection limit of this technique was lower than those of standard RT-PCR and antigen-capture ELISA; however the sensitivity and specificity of all the tests were similar [95]. A real-time RT-LAMP method, which was developed by Yu et al. and involved loop primers for the detection of the PEDV M gene, had similar sensitivity to that of real-time PCR and was 100 times more sensitive than one-step RT-PCR [97]. Additionally, the sensitivity of the real-time fluorescent RT-LAMP assay based on the detection of the PEDV M gene and using real-time fluorescent devices was at least 100 times higher than that of one-step RT-PCR [98]. A PEDV M gene real-time RT-LAMP assay also had higher sensitivity than the RT-LAMP developed for the N gene [97]. Additionally, Gou et al. established a nucleic acid visualization technique that combined RT-LAMP and a vertical flow (VF) visualization strip to detect PEDV. This M-based method demonstrated high specificity for PEDV and similar sensitivity to RT-PCR and RT-LAMP [99]. An advanced visual RT-LAMP assay combined with HNB for visual detection was 1000 times more sensitive than standard RT-PCR and comparable to rRT-PCR [97]. Most recently, Zhou et al. [100] developed a rapid, simple tool for the simultaneous detection of PEDV, PDCoV and SADS-CoV, which integrated a microfluidic chip, a real-time RT-LAMP assay and a portable microfluidic chip fluorescence detector. The centrifugal microfluidic lab-on-a-chip is the most recent innovation in the microfluidic field, and it enables multiplex high-throughput research with high efficiency and speed [101,102]. This newly developed microfluidic-RT-LAMP chip detection system presented good stability (coefficient of variation (C.V.) < 5%), a specificity of 100% and sensitivity levels of 92.24%, 92.19% and 91.23% for PEDV, PDCoV and SADS-CoV, respectively [100].

4.4. Sequencing

The genetic diversity of PEDV strains may pose a fundamental problem for PEDV testing and diagnosis. Nucleotide sequencing analyses are useful tools to identify and monitor the genetic variation and evolution of circulating PEDV strains and determine
recombination events. Comparing the nucleotide and amino acid sequences of local or regional circulating or reemerging PEDV strains with those used for the development of immunological and molecular assays ensures the reliability of those tests for as long as the regional strains and the assay development strains have high identity. Therefore, sequence information for the PEDV field strains circulating in each country should be constantly updated.

The sequences of several PEDV genes have been previously analyzed, including the $N$, $S$, $M$ and $ORF3$ genes. Those of the $S$ gene are mainly used as genetic markers for determining the genotypes of PEDV strains [103–110]. Sanger sequencing and next-generation sequencing (NGS) are the two main sequencing methods currently used for determining the PEDV sequence, with Sanger sequencing being the traditional sequencing method that needs the design and synthesis of virus-specific primers and is only capable of the sequencing of one DNA fragment at a time. In the Sanger-sequencing approach, DNA primers designed for this particular purpose are annealed to the amplified target DNA (amplified product), and then, extended by DNA polymerase by incorporating DNA nucleotides ($dATP$, $dGTP$, $dCTP$ and $dTTP$) complementary to the DNA template. In addition, small amounts of fluorophore-labeled chain-terminating dideoxynucleotides ($ddATP$, $ddGTP$, $ddCTP$ and $ddTTP$) are randomly incorporated for each nucleotide. The output of Sanger sequencing is a four-color chromatogram representing the fluorescence peak intensities associated with the ddNTPs (each labeled with a different fluorescent dye) along the DNA sequence. Sanger sequencing can read up to 500–1000 bp per reaction without complicated data analysis [111]. While Sanger sequencing is currently extensively and widely used, NGS technology is being adopted increasingly often for whole-genome sequencing. In NGS, genomic material in a clinical specimen is fragmented, randomly amplified and used to prepare a library of genomic fragments that are then sequenced by using one of several common strategies. A major advantage of NGS is that it has no need for target-specific primers, unlike Sanger sequencing. By virtue of this, NGS has the ability to discover novel, unknown PEDV strains and provides the opportunity to detect recombination events in PEDV strains [112,113]. It also sequences a full-length viral genome rapidly in one sequencing run. Although NGS sequencing technology is the foundation of valuable techniques for the diagnosis of entire genomes of viruses, it has some disadvantages, including cost and the requirements for specialized instruments and trained personnel. In particular, proficiency in using advanced bioinformatic tools is required for assembly and mapping to reference genomes. Furthermore, the detection of viral genomes can be problematic because of the low amounts of genetic material sometimes contained in clinical samples. Therefore, the applicability of NGS in clinical diagnostic methodologies is very limited.

4.5. CRISPR–Cas Technology

Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas is a nucleic acid detection technique which allows specific sequences in the genome to be added, removed or modified using the Cas12 and 13 proteins. By combining Cas proteins with a preamplification step such as PCR, RPA or LAMP and a single-stranded DNA–fluorescently quenched (ssDNA-FQ) reporter, various biosensing platforms have been developed. This system shows great potential for integration into novel, accurate, fast and convenient molecular diagnostic methods [114].

Yang et al. first created a rapid method to distinguish PEDV wild-type strains from attenuated vaccine strains by combining reverse-transcription–enzymatic recombinase amplification (RT-ERA) with the CRISPR–Cas12a system [115]. The total detection time of this assay was approximately 30 min and the results were visible under blue LED light. The method was sensitive, being capable of detecting two copies of genomic DNA, and specific, showing no cross-reactivity with other porcine viruses. Recently, Liu et al. developed a multiplex nucleic acid detection method based on CRISPR–Cas12a and multiplex RT-LAMP for the detection of four porcine diarrhea coronaviruses: PEDV, TGEV, PDCoV
and SADS-CoV. This newly developed assay achieved single-copy sensitivity with no cross-reactivity. The results were visible to the naked eye using a ROX-labeled ssDNA-FQ reporter [116]. Generally, the methods described above are sensitive, capable of rapid detection, do not require expensive equipment or long training and can be performed at the point of care.

5. Conclusions

In the absence of effective vaccines, early, rapid and accurate diagnosis of PEDV is crucial for the prevention and control of the spread of disease. Therefore, the development and selection of reliable, appropriate diagnostic tests is very important. Multiple approaches have been explored and methods implemented to improve the detection of PEDV. Each of the tests has its own unique advantages and disadvantages (Table 3), and thus, as far as is practicable, several methods are combined to avoid the drawbacks of using a single method. While molecular assays allow the identification of the nucleic acid of PEDV, serological assays provide information about the prevalence of PEDV infection and the efficiency of vaccination strategies, and may be helpful in predicting the duration of immunity in piglets. Molecular assays have high sensitivity and specificity but require trained staff and specialized equipment, and the associated costs can be high. In contrast, antibody-based assays are generally cheaper and generally more accessible to untrained users. However, serological techniques are less sensitive than nucleic acid detection methods. While molecular and antibody-based methods will likely continue to dominate in the diagnosis of PEDV, newer technologies such as NGS could complement them and enhance their utility. Next-generation sequencing may provide valuable information on PEDV heterogeneity and evolution and may be applied to identify new or reemerging viruses. Furthermore, the new generation method based on nonspecific DNA cleavage in CRISPR–Cas systems promises major advances in the diagnosis of PEDV.

Table 3. The advantages and disadvantages of serological assays and the nucleic acid test for PEDV diagnostic purposes.

| Method          | Advantages                                                                 | Disadvantages                                                                 |
|-----------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| ELISA           | High sensitivity and specificity, multiple formats available, not very       | Needs infrastructure and qualified personnel, and nonspecific result can occur   |
|                 | expensive, medium turnaround time, IgG or IgA antibody detection and         |                                                                                 |
|                 | amenable to high-volume testing                                             |                                                                                 |
| Antigen ELISA   | High sensitivity and specificity, amenable to high-volume testing, not very  | Needs infrastructure and qualified personnel, nonspecific reaction can occur     |
|                 | expensive and medium turnaround time                                        | and fecal samples should be collected immediately after appearance of clinical  |
|                 |                                                                             | symptoms                                                                      |
| FMIA            | Sensitive, specific, rapid, simultaneous detection of antibodies against     | Expensive, and requires specialized equipment, reagents and qualified personnel  |
|                 | multiple pathogens and amenable to high-volume testing                      |                                                                                |
| VN              | High specificity, detected neutralizing antibodies and not very expensive    | Time-consuming, requires well-trained technicians, subjective results, cyto     |
|                 |                                                                             | toxic effects can occur and requires Vero cell culture                        |
| FFN             | High specificity, cytopathic effect is not interpreted, shorter turnaround   | Requires specialized equipment, reagents and qualified personnel, and requires   |
|                 | time than VN, can be quantitative or qualitative and detected               | Vero cell culture                                                              |
|                 | neutralizing antibodies                                                     |                                                                                |


Table 3. Cont.

| Method                        | Advantages                                                                 | Disadvantages                                                                                                                                 |
|-------------------------------|-----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| IFA                           | High specificity and medium turnaround time                                  | Requires specialized equipment, reagents and qualified personnel; lower diagnostic sensitivity than FFN; subjective results; and requires Vero cell culture |
| IC                            | No need for laboratory equipment and qualified personnel, portable, rapid turnaround, speedy results, simple test procedure and relatively inexpensive to produce | Low specificity and sensitivity, most IC assays are not quantitative and are not suitable for large-scale screening, one step assay and nonspecific results can occur |
| RT-PCR/nRT-PCR                | Higher sensitivity and specificity, and can be multiplexed                   | Expensive; requires specialized equipment, reagents and qualified personnel; time-consuming; unable to quantify the target DNA; only qualitative test; and not suitable for large-scale screening |
| qRT-PCR                       | Higher sensitivity and specificity, more sensitive than RT-PCR, quantitative application, medium turnaround time, can be multiplexed and amenable to high-volume testing | Expensive; requires specialized equipment, reagents and qualified personnel; and needs quality control |
| Nucleic acid tests            |                                                                            |                                                                                                                                               |
| LAMP                          | Simple, fast, cheap, no special equipment, high sensitivity, can be quantitative or qualitative, results can be read by eye and the temperature stability of the reagents enables its use in field condition | Requires rather qualified personnel, primer design can be challenging, nonspecific binding of primers can cause false-positive results, and for qualitative results, specialized equipment is required |
| Sequencing                    | High accuracy, genotyping, provides the opportunity to detect recombination events, NGS has the ability to diagnose entire genome and discover novel, unknown PEDV strains, and using NGS, there is no need for target-specific primers | Expensive; requires specialized equipment; reagents and bioinformatics experts; and difficult for widespread testing |
| CRISPR                        | Higher specificity and sensitivity, accuracy, rapid, can be used alone or with established amplification methods and can be multiplexed | Generally, requires pre-amplification step and qualitative detection                                                                 |

ELISA—enzyme-linked immunosorbent assay; FMIA—fluorescent microsphere immunoassay; VN—virus neutralization assay; FFN—fluorescent focus neutralization; IFA—indirect immunofluorescence assay; IC—immunochromatography assay; RT-PCR—reverse-transcription polymerase chain reaction; nRT-PCR—nested reverse-transcription polymerase chain reaction; qRT-PCR—real-time reverse-transcription polymerase chain reaction; LAMP—loop-mediated isothermal amplification assays; CRISPR—clustered regularly interspaced short palindromic repeats.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The author declares no conflict of interest.
References

1. Song, D.; Zhou, X.; Peng, Q.; Chen, Y.; Zhang, F.; Huang, T.; Zhang, T.; Li, A.; Huang, D.; Wu, Q.; et al. Newly Emerged Porcine Deltacoronavirus Associated With Diarrhoea in Swine in China: Identification, Prevalence and Full-Length Genome Sequence Analysis. Transl. Emerg. Dis. 2015, 62, 575–580. [CrossRef] [PubMed]

2. Alvarez, J.; Sarradell, J.; Morrison, R.; Perez, A. Impact of porcine epidemic diarrhea on performance of growing pigs. PLoS ONE 2015, 10, e0120532. [CrossRef] [PubMed]

3. Pensaert, M.B.; de Bouck, P. A new coronavirus-like particle associated with diarrhea in swine. Arch. Virol. 1978, 58, 243–247. [CrossRef]

4. Diel, D.G.; Lawson, S.; Okda, F.; Singrey, A.; Clement, T.; Fernandes, M.H.V.; Christopher-Hennings, J.; Nelson, E.A. Porcine epidemic diarrhea virus: An overview of current virological and serological diagnostic methods. Virus Res. 2016, 226, 60–70. [CrossRef] [PubMed]

5. Lee, C. Porcine epidemic diarrhea virus: An emerging and re-emerging epizootic swine virus. Virol. J. 2015, 12, 193. [CrossRef]

6. Sekhon, S.S.; Nguyen, P.L.; Ahn, J.Y.; Lee, K.A.; Lee, L.; Kim, S.Y.; Yoon, H.; Park, J.; Ko, J.H.; Kim, Y.H. Porcine epidemic diarrhea (PED) infection, diagnosis and vaccination: A mini review. Toxicol. Environ. Health Sci. 2016, 8, 277–289. [CrossRef] [PubMed]

7. Li, C.; Li, W.; Lucio de Esesarte, E.; Guo, H.; van den Elzen, P.; Aarts, E.; van den Born, E.; Rottier, P.J.M.; Bosch, B.J. Cell Attachment Domains of the Porcine Epidemic Diarrhea Virus Spike Protein Are Key Targets of Neutralizing Antibodies. J. Virol. 2017, 91, e00273-17. [CrossRef]

8. Fan, B.; Jiao, D.; Zhao, X.; Pang, F.; Xiao, Q.; Yu, Z.; Mao, A.; Guo, R.; Yuan, W.; Zhao, P.; et al. Characterization of Chinese Porcine Epidemic Diarrhea Virus with Novel Insertions and Deletions in Genome. Sci. Rep. 2017, 7, 44209. [CrossRef]

9. Wang, D.; Fang, L.; Xiao, S. Porcine epidemic diarrhea in China. Virus Res. 2016, 226, 7–13. [CrossRef] [PubMed]

10. Guo, J.; Fang, L.; Ye, X.; Chen, J.; Xu, S.; Zhu, X.; Miao, Y.; Wang, D.; Xiao, S. Evolutionary and genotypic analyses of global porcine epidemic diarrhea virus strains. Transbound. Emerg. Dis. 2019, 66, 111–118. [CrossRef]

11. Sun, D.; Wang, X.; Wei, S.; Chen, J.; Feng, L. Epidemiology and vaccine of porcine epidemic diarrhea virus in China: A mini-review. J. Vet. Med. Sci. 2016, 78, 355–363. [CrossRef]

12. Oh, J.S.; Song, D.S.; Yang, J.S.; Song, J.Y.; Moon, H.J.; Kim, T.Y.; Park, B.K. Comparison of an enzyme-linked immunosorbent assay with serum neutralization test for serodiagnosis of porcine epidemic diarrhea virus infection. J. Vet. Sci. 2005, 6, 349–3529. [CrossRef]

13. Gerber, P.F.; Gong, Q.; Huang, Y.-W.; Wang, C.; Holtkamp, D.; Opriessnig, T. Detection of antibodies against porcine epidemic diarrhea virus in serum and colostrum by indirect ELISA. Vet. J. 2014, 202, 33–36. [CrossRef]

14. Chang, C.Y.; Peng, J.Y.; Cheng, Y.H.; Chang, Y.C.; Wu, Y.T.; Tsai, P.S.; Chiou, H.Y.; Jeng, C.R.; Chang, H.W. Development and comparison of enzyme-linked immunosorbent assays based on recombinant trimeric full-length and truncated spike proteins for detecting antibodies against porcine epidemic diarrhea virus. BMC Vet. Res. 2019, 15, 421. [CrossRef] [PubMed]

15. Chang, C.Y.; Hsu, W.T.; Chao, Y.C.; Chang, H.W. Display of Porcine Epidemic Diarrhea Virus Spike Protein on Baculovirus to Improve Immunogenicity and Protective Efficacy. Viruses 2018, 10, 346. [CrossRef] [PubMed]

16. Okda, F.; Liu, X.; Singrey, A.; Clement, T.; Nelson, J.; Christopher-Hennings, J.; Nelson, E.A.; Lawson, S. Development of an indirect ELISA, blocking ELISA, fluorescent microsphere immunoassay and fluorescent focus neutralization assay for serologic evaluation of exposure to North American strains of Porcine Epidemic Diarrhea Virus. BMC Vet. Res. 2015, 11, 180. [CrossRef]

17. Aydin, S. A short history, principles, and types of ELISA, and our laboratory experience with peptide/protein analyses using ELISA. Peptides 2015, 72, 4–15. [CrossRef] [PubMed]

18. Sozzi, E.; Moreno, A.; Lelli, D.; Perulli, S.; Prosperi, A.; Brocchi, E.; Capucci, L.; Papetti, A.; Giacomini, E.; Alborali, G.L.; et al. Development and validation of a monoclonal antibody-based competitive ELISA for detection of antibodies against porcine epidemic diarrhoea virus (PEDV). Res. Vet. Sci. 2018, 121, 106–110. [CrossRef] [PubMed]

19. Song, D.; Park, B. Porcine epidemic diarrhoea virus: A comprehensive review of molecular epidemiology, diagnosis, and vaccines. Virus Genes 2012, 44, 167–175. [CrossRef] [PubMed]

20. Wang, K.; Xie, C.; Zhang, J.; Zhang, W.; Yang, D.; Yu, L.; Jiang, Y.; Yang, S.; Gao, F.; Yang, Z.; et al. The Identification and Characterization of Two Novel Epitopes on the Nucleocapsid Protein of the Porcine Epidemic Diarrhea Virus. Virus Res. 2016, 20, 39010. [CrossRef]

21. Hou, X.L.; Yu, L.Y.; Liu, J. Development and evaluation of enzyme-linked immunosorbent assay based on recombinant nucleocapsid protein for detection of porcine epidemic diarrhoea virus (PEDV) antibodies. Vet. Microbiol. 2007, 123, 86–92. [CrossRef]

22. Gimenez-Lirola, L.G.; Zhang, J.; Carrillo-Avila, J.A.; Chen, Q.; Magtoto, R.; Poonsuk, K.; Baum, D.H.; Piñeyro, P.; Zimmerman, J. Reactivity of Porcine Epidemic Diarrhea Virus Structural Proteins to Antibodies against Porcine Enteric Coronaviruses: Diagnostic Implications. J. Clin. Microbiol. 2017, 55, 1426–1436. [CrossRef] [PubMed]

23. Lin, C.M.; Gao, X.; Oka, T.; Vlasova, A.N.; Esseili, M.A.; Wang, Q.; Saif, L.J. Antigenic relationships among porcine epidemic diarrhoea virus and transmissible gastroenteritis virus strains. J. Virol. 2015, 89, 3332–3342. [CrossRef]

24. Paudel, S.; Park, J.E.; Jang, H.; Shin, H.J. Comparison of serum neutralization and enzyme-linked immunosorbent assay on sera from porcine epidemic diarrhea vaccinated pigs. Vet. Q. 2014, 34, 218–223. [CrossRef] [PubMed]

25. Srijangwad, A.; Tripipat, T.; Saeng-Chuto, K.; Jermsujarit, P.; Tantituvanont, A.; Okabayashi, T.; Nilubol, D. Development and validation of indirect ELISA for antibody detection against different protein antigens of porcine epidemic diarrhoea virus in the colostrum and milk of sows. J. Immunol. Methods 2021, 494, 113045. [CrossRef] [PubMed]
26. Chang, S.H.; Bae, J.L.; Kang, T.J.; Kim, J.; Chung, G.H.; Lim, C.W.; Laude, H.; Yang, M.S.; Jang, Y.S. Identification of the epitope region capable of inducing neutralizing antibodies against the porcine epidemic diarrhea virus. *Mol. Cells* 2002, 14, 295–299. [PubMed]

27. Sun, D.B.; Feng, L.; Shi, H.Y.; Chen, J.F.; Liu, S.W.; Chen, H.Y.; Wang, Y.F. Spike protein region (aa 636789) of porcine epidemic diarrhea virus is essential for induction of neutralizing antibodies. *Acta Virol.* 2007, 51, 149–156. [PubMed]

28. Cruz, D.J.; Kim, C.J.; Shin, H.J. The GPRLLQPY motif located at the carboxy-terminal of the spike protein induces antibodies that neutralize Porcine epidemic diarrhea virus. *Virus Res.* 2008, 132, 192–196. [CrossRef] [PubMed]

29. Okda, F.A.; Lawson, S.; Singrey, A.; Nelson, J.; Hain, K.S.; Joshi, L.R.; Christopher-Hennings, J.; Nelson, E.A.; Diel, D.G. The S2 glycoprotein subunit of porcine epidemic diarrhea virus contains immunodominant neutralizing epitopes. *Virology* 2017, 509, 185–194. [CrossRef]

30. Sun, D.; Feng, L.; Shi, H.; Chen, J.; Cui, X.; Chen, H.; Liu, S.; Tong, Y.; Wang, Y.; Tong, G. Identification of two novel B cell epitopes on porcine epidemic diarrhea virus spike protein. *Vet. Microbiol.* 2008, 131, 73–81. [CrossRef] [PubMed]

31. Kong, N.; Meng, Q.; Jiao, Y.; Wu, Y.; Zhu, Y.; Wang, H.; Sun, D.; Dong, S.; Zhai, H.; Tong, W.; et al. Identification of a novel B-cell epitope in the spike protein of porcine epidemic diarrhea virus. *Virology* 2020, 17, 46. [CrossRef]

32. Oh, J.; Lee, K.W.; Choi, H.W.; Lee, C. Immunogenicity and protective efficacy of recombinant S1 domain of the porcine epidemic diarrhea virus spike protein. *Arch. Virol.* 2014, 159, 2977–2987. [CrossRef]

33. Zhang, Z.; Chen, J.; Shi, H.; Chen, X.; Shi, D.; Feng, L.; Yang, B. Identification of a conserved linear B-cell epitope in the M protein of porcine epidemic diarrhea virus. *J. Virol.* 2012, 9, 225. [CrossRef]

34. Lei, X.M.; Yang, Y.L.; He, Y.Q.; Peng, L.; Zhao, P.; Xu, S.Y.; Cao, H.; Fang, P.; Qiu, W.; Qin, P.; et al. Specific recombinant proteins of porcine epidemic diarrhea virus are immunogenic, revealing their potential use as diagnostic markers. *Vet. Microbiol.* 2019, 236, 108387. [CrossRef]

35. Gui, R.; Shi, H.Y.; Liu, W.; Feng, L.; Yang, K.L.; Guo, R.; Liang, W.; Yuan, F.Y.; Duan, Z.Y.; Liu, Z.W.; et al. Development of sandwich Enzyme-Linked Immunosorbent Assay for the detection of porcine epidemic diarrhea virus in fecal samples. *Microb. Pathog.* 2018, 122, 151–155. [CrossRef]

36. Ma, Z.; Wang, T.; Li, Z.; Guo, X.; Tian, Y.; Li, Y.; Xiao, S. A novel biotinylated nanobody-based blocking ELISA for the rapid and sensitive clinical detection of porcine epidemic diarrhea virus. *J. Nanobiotechnology* 2019, 17, 96. [CrossRef]

37. Bao, F.; Wang, L.; Zhao, X.; Lu, T.; Na, A.M.; Wang, X.; Cao, J.; Du, Y. Preparation and characterization of a single-domain antibody specific for the porcine epidemic diarrhea virus spike protein. *AMB Express* 2019, 9, 104. [CrossRef]

38. Kimpston-Burksgen, K.; Mora-Diaz, J.C.; Roby, P.; Bjostrom-Kraft, J.; Main, R.; Bosse, R.; Giménez-Lirola, L.G. Characterization of the Humoral Immune Response to Porcine Epidemic Diarrhea Virus Infection under Experimental and Field Conditions Using an AlphalISA Platform. *Pathogens* 2020, 9, 233. [CrossRef]

39. Malbec, R.; Kimpston-Burksgen, K.; Vandenkoornhuyse, E.; Olivier, C.; Souplet, V.; Audebert, C.; Carrillo-Ávila, J.A.; Baum, D.; Giménez-Lirola, L. Agrodiag PorCoV: A multiplex immunoassay for the differential diagnosis of porcine enteric coronaviruses. *J. Immunol. Methods* 2020, 483, 112808. [CrossRef]

40. Christopher-Hennings, J.; Araujo, K.P.; Souza, C.J.; Fang, Y.; Lawson, S.; Nelson, E.A.; Clement, T.; Dunn, M.; Lunney, J.K. Opportunities for bead-based multiplex assays in veterinary diagnostic laboratories. *J. Vet. Diagn. Invest.* 2013, 25, 671–691. [CrossRef]

41. Thomas, J.T.; Chen, Q.; Gauger, P.C.; Giménez-Lirola, L.G.; Sinha, A.; Harmon, K.M.; Madson, D.M.; Burrough, E.R.; Magstadt, D.R.; Salzbrunner, H.M.; et al. Effect of Porcine Epidemic Diarrhea Virus Infectious Doses on Infection Outcomes in Naive Conventional Neonatal and Weaned Pigs. *PLoS ONE* 2015, 10, e0139266. [CrossRef]

42. Clement, T.; Singrey, A.; Lawson, S.; Okda, F.; Nelson, E.; Diel, D.; Nelson, E.A.; Christopher-Hennings, J. Measurement of neutralizing antibodies against porcine epidemic diarrhea virus in sow serum, colostrum, and milk samples and piglet serum samples after feedback. *J. Swine Health Prod.* 2016, 24, 1–10.

43. Sarmento, L.V.; Poonsuk, K.; Tian, L.; Mora-Diaz, J.C.; Main, R.G.; Baum, D.H.; Zimmerman, J.J.; Giménez-Lirola, L.G. Detection of porcine epidemic diarrhea virus-neutralizing antibody using high-throughput imaging cytometry. *J. Vet. Diagn. Invest.* 2020, 32, 324–328. [CrossRef]

44. Lin, H.; Zhou, H.; Gao, L.; Li, B.; He, K.; Fan, H. Development and application of an indirect ELISA for the detection of antibodies to porcine epidemic diarrhea virus based on a recombinant spike protein. *BMC Vet. Res.* 2018, 14, 243. [CrossRef]

45. Wang, X.; Chen, J.; Shi, D.; Shi, H.; Zhang, X.; Yuan, J.; Jiang, S.; Feng, L. Immunogenicity and antigenic relationships among spike proteins of porcine epidemic diarrhea virus subtypes G1 and G2. *Arch. Virol.* 2016, 161, 537–547. [CrossRef]

46. Zhou, G.; Mao, X.; Juncker, D. Immunochromatographic assay on thread. *Anal. Chem.* 2012, 84, 7736–7743. [CrossRef]

47. Posthuma-Trumpie, G.A.; Korf, J.; van Amerongen, A. Lateral flow (immuno)assay: Its strengths, weaknesses, opportunities and threats. A literature survey. *Anal. Bioanal. Chem.* 2009, 393, 569–582. [CrossRef]

48. Kim, Y.K.; Lim, S.I.; Cho, I.S.; Cheong, K.M.; Lee, E.J.; Lee, S.O.; Kim, J.B.; Kim, J.H.; Jeong, D.S.; An, B.H.; et al. A novel diagnostic approach to detecting porcine epidemic diarrhea virus: The lateral immunochromatography assay. *J. Virol. Methods* 2015, 225, 4–8. [CrossRef]

49. Xu, F.; Jin, Z.; Zou, S.; Chen, C.; Song, Q.; Deng, S.; Xiao, W.; Zhang, X.; Jia, A.; Tang, Y. EuNPs-mAb fluorescent probe based immunochromatographic strip for rapid and sensitive detection of porcine epidemic diarrhea virus. *Talanta* 2020, 214, 120865. [CrossRef]
50. Bian, H.; Xu, F.; Jia, Y.; Wang, L.; Deng, S.; Jia, A.; Tang, Y. A new immunochromatographic assay for on-site detection of porcine epidemic diarrhea virus based on monoclonal antibodies prepared by using cell surface fluorescence immunosorbent assay. BMC Vet. Res. 2019, 15, 32. [CrossRef]

51. Xiao, W.; Huang, C.; Xu, F.; Yan, J.; Bian, H.; Fu, Q.; Xie, K.; Wang, L.; Tang, Y. A simple and compact smartphone-based device for the quantitative readout of colloidal gold lateral flow immunoassay strips. Sens. Actuators B Chem. 2018, 266, 63–70. [CrossRef]

52. Zou, S.; Wu, L.; Li, G.; Wang, J.; Cao, D.; Xu, T.; Jia, A.; Tang, Y. Development of an accurate lateral flow immunoassay for PEDV detection in swine fecal samples with a filter pad design. Anim. Dis. 2021, 1, 27. [CrossRef]

53. Liu, J.; Gao, R.; Shi, H.; Cong, G.; Chen, J.; Zhang, X.; Shi, D.; Cao, L.; Wang, X.; Zhang, J.; et al. Development of a rapid immunochromatographic strip test for the detection of porcine epidemic diarrhea virus specific S IgA in colostrum. J. Virol. Methods 2020, 279, 113855. [CrossRef]

54. Sozzi, E.; Luppi, A.; Lelli, D.; Martin, A.M.; Canelli, E.; Brocchi, E.; Lavazza, A.; Cordioli, P. Comparison of enzyme-linked immunosorbent assay and RT-PCR for the detection of porcine epidemic diarrhoea virus. Res. Vet. Sci. 2010, 88, 166–168. [CrossRef]

55. Wang, Z.; Jiuyuan, Y.; Su, C.; Xinyuan, Q.; Lijing, L. Development of an antigen capture enzyme-linked immunosorbent assay for virus detection based on monoclonal antibodies. Viral. Immunol. 2015, 28, 184–189. [CrossRef]

56. Ren, X.; Suo, S.; Jang, Y.S. Development of a porcine epidemic diarrhea virus M protein-based ELISA for virus detection. Biotechnol. Lett. 2011, 33, 215–220. [CrossRef]

57. Fan, B.; Sun, J.; Zhu, L.; Zhou, J.; Zhao, Y.; Yu, Z.; Sun, B.; Guo, R.; He, K.; Li, B. Development of a Novel Double Antibody Sandwich Quantitative Enzyme-Linked Immunosorbent Assay for Detection of Porcine Epidemic Diarrhea Virus Antigen. Front. Vet. Sci. 2020, 7, 540248. [CrossRef]

58. Rodák, L.; Václíková, L.; Smid, B.; Nevoránková, Z. An ELISA optimized for porcine epidemic diarrhoea virus detection in faeces. Vet. Microbiol. 2005, 105, 9–17. [CrossRef]

59. Chen, Q.; Li, G.; Stasko, J.; Thomas, J.T.; Stensland, W.R.; Pillatzki, A.E.; Gauger, P.C.; Schwartz, K.J.; Madson, D.; Yoon, K.J.; et al. Isolation and characterization of porcine epidemic diarrhoea viruses associated with the 2013 disease outbreak among swine in the United States. J. Clin. Microbiol. 2014, 52, 234–243. [CrossRef]

60. Jung, K.; Saif, L.J. Porcine epidemic diarrhoea virus infection: Etiology, epidemiology, pathogenesis and immunopathogenesis. Vet. J. 2015, 204, 134–143. [CrossRef]

61. Bjostrom-Kraft, J.; Woodward, K.; Giménez-Liriola, L.; Rotolo, M.; Wang, C.; Sun, Y.; Lasley, P.; Zhang, J.; Baum, D.; Gauger, P.; et al. Porcine epidemic diarrhoea virus (PEDV) detection and antibody response in commercial growing pigs. BMC Vet. Res. 2016, 12, 99. [CrossRef] [PubMed]

62. Ishikawa, K.; Sekiguchi, H.; Ogino, T.; Suzuki, S. Direct and rapid detection of porcine epidemic diarrhoea virus by RT-PCR. J. Virol. Methods 1997, 69, 191–195. [CrossRef] [PubMed]

63. Kubota, S.; Sasaki, O.; Aminoto, K.; Okada, N.; Kitazima, T.; Yasuhara, H. Detection of porcine epidemic diarrhoea virus using polymerase chain reaction and comparison of the nucleocapsid protein genes among strains of the virus. J. Vet. Med. Sci. 1999, 61, 827–830. [CrossRef] [PubMed]

64. Lee, C.; Park, C.K.; Lyoo, Y.S.; Lee du, S. Genetic differentiation of the nucleocapsid protein of Korean isolates of porcine epidemic diarrhoea virus by RT-PCR based restriction fragment length polymorphism analysis. Vet. J. 2008, 178, 138–140. [CrossRef] [PubMed]

65. Kweon, C.H.; Lee, J.G.; Han, M.G.; Kang, Y.B. Rapid diagnosis of porcine epidemic diarrhoea virus infection by polymerase chain reaction. J. Vet. Med. Sci. 1997, 59, 231–232. [CrossRef] [PubMed]

66. Zhu, Y.; Wang, G.H.; Cui, Y.D.; Cui, S.J. Establishment of a nanoparticle-assisted RT-PCR assay to distinguish field strains and attenuated strains of porcine epidemic diarrhea virus. Arch. Virol. 2016, 161, 2543–2547. [CrossRef]

67. Zhao, P.D.; Bai, J.; Jiang, P.; Tang, T.S.; Li, Y.; Tan, C.; Shi, X. Development of a multiplex TaqMan probe-based real-time PCR for discrimination of variant and classical porcine epidemic diarrhoea viruses. J. Virol. Methods 2014, 206, 150–155. [CrossRef] [PubMed]

68. Su, Y.; Liu, J.; Chen, Y.; Xing, G.; Hao, H.; Wei, Q.; Liang, Y.; Xie, W.; Li, D.; Huang, H.; et al. A novel duplex TaqMan probe-based real-time RT-qPCR for detecting and differentiating classical and variant porcine epidemic diarrhoea viruses. Mol. Cell. Probes 2018, 37, 6–11. [CrossRef] [PubMed]

69. Zhou, X.; Zhang, T.; Song, D.; Huang, T.; Peng, Q.; Chen, Y.; Li, A.; Zhang, F.; Wu, Q.; Ye, Y.; et al. Comparison and evaluation of conventional RT-PCR, SYBR green I and TaqMan real-time RT-PCR assays for the detection of porcine epidemic diarrhoea virus. Mol. Cell. Probes 2017, 33, 36–41. [CrossRef]

70. Song, D.S.; Kang, B.K.; Oh, J.S.; Ha, G.W.; Yang, J.S.; Moon, H.J.; Jang, Y.S.; Park, B.K. Multiplex reverse transcription-PCR for rapid differential detection of porcine epidemic diarrhoea virus, transmissible gastroenteritis virus, and porcine group A rotavirus. J. Vet. Diagn. Invest. 2006, 18, 278–281. [CrossRef] [PubMed]

71. Zhao, J.; Shi, B.J.; Huang, X.G.; Peng, M.Y.; Zhang, X.M.; He, D.N.; Pang, R.; Zhou, B.; Chen, P.Y. A multiplex RT-PCR assay for rapid and differential diagnosis of four diarrhoea associated viruses in field samples from pig farms in East China from 2010 to 2012. J. Virol. Methods 2013, 194, 107–112. [CrossRef] [PubMed]

72. Ding, G.; Fu, Y.; Li, B.; Chen, J.; Wang, J.; Yin, B.; Sha, W.; Liu, G. Development of a multiplex RT-PCR for the detection of major diarrhoeal viruses in pig herds in China. Transbound. Emerg. Dis. 2020, 67, 678–685. [CrossRef] [PubMed]
73. Zhao, Y.; Liu, F.; Li, Q.; Wu, M.; Lei, L.; Pan, Z. A multiplex RT-PCR assay for rapid and simultaneous detection of four RNA viruses in swine. *J. Virol. Methods*. 2019, 269, 38–42. [CrossRef] [PubMed]

74. Ben Salem, A.N.; Chupin Sergej, A.; Bjadovskaya Olga, P.; Andreeva Olga, G.; Mahjoub, A.; Prokhwatilova Larissa, B. Multiplex nested RT-PCR for the detection of porcine enteric viruses. *J. Virol. Methods*. 2010, 165, 283–293. [CrossRef]

75. Jiang, C.; He, H.; Zhang, C.; Zhang, X.; Han, J.; Zhang, H.; Luo, Y.; Wu, Y.; Wang, Y.; Ge, B.; et al. One-step triplex reverse-transcription PCR detection of porcine epidemic diarrhea virus, porcine sapelovirus, and porcine sapovirus. *J. Vet. Diagn. Investig*. 2019, 31, 909–912. [CrossRef] [PubMed]

76. Kim, S.Y.; Song, D.S.; Park, B.K. Differential detection of transmissible gastroenteritis virus and porcine epidemic diarrhea virus by duplex RT-PCR. *J. Vet. Diagn. Investig*. 2001, 13, 516–520. [CrossRef] [PubMed]

77. Kim, O.; Choi, C.; Kim, B.; Chae, C. Detection and differentiation of porcine epidemic diarrhoea virus and transmissible gastroenteritis virus in clinical samples by multiplex RT-PCR. *Vet. Rec.* 2000, 146, 637–640. [CrossRef] [PubMed]

78. Bigultz, L.; Brown, P.; Bernard, C.; Blanchard, Y.; Grassland, B. Porcine epidemic diarrhea virus: Viral RNA detection and quantification using a validated one-step real time RT-PCR. *J. Virol. Methods*. 2020, 283, 113906. [CrossRef]

79. Kim, S.H.; Kim, I.J.; Pyo, H.M.; Tark, D.S.; Song, J.Y.; Hyun, B.H. Multiplex real-time RT-PCR for the simultaneous detection and quantification of transmissible gastroenteritis virus and porcine epidemic diarrhea virus. *J. Virol. Methods*. 2007, 146, 172–177. [CrossRef] [PubMed]

80. Wang, L.; Zhang, Y.; Byrum, B. Development and evaluation of a duplex real-time RT-PCR for detection and differentiation of virulent and variant strains of porcine epidemic diarrhea viruses from the United States. *J. Virol. Methods*. 2014, 207, 154–157. [CrossRef] [PubMed]

81. Miller, L.C.; Crawford, K.K.; Lager, K.M.; Kellner, S.G.; Brockmeier, S.L. Evaluation of two real-time polymerase chain reaction assays for Porcine epidemic diarrhea virus (PEDV) to assess PEDV transmission in growing pigs. *J. Vet. Diagn. Investig*. 2016, 28, 20–29. [CrossRef]

82. Zhang, J.; Tsai, Y.L.; Lee, P.Y.; Chen, Q.; Zhang, Y.; Chiang, C.J.; Shen, Y.H.; Li, F.C.; Chang, H.F.; Gauger, P.C.; et al. Evaluation of two singleplex reverse transcription-Insulated isothermal PCR tests and a duplex real-time RT-PCR test for the detection of porcine epidemic diarrhea virus and porcine deltacoronavirus. *J. Virol. Methods*. 2016, 234, 34–42. [CrossRef] [PubMed]

83. Pan, Z.; Lu, J.; Wang, N.; He, W.T.; Zhang, L.; Zhao, W.; Su, S. Development of a TaqMan-probe-based multiplex real-time PCR for the simultaneous detection of emerging and reemerging swine coronaviruses. *Virology 2020*, 11, 707–718. [CrossRef]

84. Zhu, H.; Rawal, G.; Aljets, E.; Yin-Im, W.; Yang, Y.L.; Huang, Y.W.; Krueger, K.; Gauger, P.; Main, R.; Zhang, J. Development and Clinical Applications of a 5-Plex Real-Time RT-PCR for Swine Enteric Coronavirus. *Viruses 2022*, 14, 1536. [CrossRef]

85. Huang, X.; Chen, J.; Yao, G.; Guo, Q.; Wang, J.; Liu, G. A TaqMan-probe-based multiplex real-time RT-qPCR for simultaneous detection of porcine enteric coronaviruses. *Appl. Microbiol. Biotechnol. 2019*, 103, 4943–4952. [CrossRef] [PubMed]

86. Zheng, L.L.; Cui, J.T.; Han, H.Y.; Hou, H.L.; Wang, L.; Liu, F.; Chen, H.Y. Development of a duplex SYBR GreenI based real-time PCR assay for detection of porcine epidemic diarrhea virus and porcine bocavirus3/4/5. *Mol. Cell. Probes 2020*, 51, 101544. [CrossRef] [PubMed]

87. Liu, J.; Li, L.M.; Han, J.Q.; Sun, T.R.; Zhao, X.; Xu, R.T.; Song, Q.Y. A TaqMan probe-based real-time PCR to differentiate porcine epidemic diarrhea virus from virulent strains of vaccine strains. *Mol. Cell. Probes 2019*, 45, 37–42. [CrossRef]

88. Han, H.Y.; Zheng, H.H.; Zhao, Y.; Tian, R.B.; Xu, P.L.; Hou, H.L.; Chen, H.Y.; Yang, M.F. Development of a SYBR green I-based duplex real-time fluorescence quantitative PCR assay for the simultaneous detection of porcine epidemic diarrhea virus and porcine circovirus 3. *Mol. Cell. Probes 2019*, 44, 44–50. [CrossRef]

89. Wen, D.; Liu, G.; Opriessning, T.; Yang, Z.; Jiang, Y. Simultaneous detection of five pig viruses associated with enteric disease in pigs using EvaGreen real-time PCR combined with melting curve analysis. *J. Virol. Methods*. 2019, 268, 1–8. [CrossRef] [PubMed]

90. Si, G.; Niu, J.; Zhou, X.; Xie, Y.; Chen, Z.; Li, G.; Chen, R.; He, D. Use of dual priming oligonucleotide system-based multiplex RT-PCR assay to detect five diarrheal viruses in pig herds in South China. *AMB Express 2021*, 11, 99. [CrossRef] [PubMed]

91. Jia, S.; Feng, B.; Wang, Z.; Ma, Y.; Gao, X.; Jiang, Y.; Cui, W.; Qiao, X.; Tang, L.; Li, Y.; et al. Dual priming oligonucleotide (DPO)-based real-time RT-PCR assay for accurate differentiation of four major viruses causing porcine viral diarrhea. *Mol. Cell. Probes 2019*, 47, 101435. [CrossRef]

92. Toley, B.J.; Covelli, I.; Belousov, Y.; Ramachandran, S.; Kline, E.; Scarr, N.; Vermeulen, N.; Mahoney, W.; Lutz, B.R.; Yager, P. Isothermal strand displacement amplification (iSDA): A rapid and sensitive method of nucleic acid amplification for point-of-care diagnosis. *Analyst 2015*, 140, 7540–7549. [CrossRef]

93. Piepenburg, O.; Williams, C.H.; Stemple, D.L.; Armes, N.A. DNA detection using recombination proteins. *PLoS Biol.* 2006, 4, e204. [CrossRef]

94. Xu, G.; Hu, L.; Zhong, H.; Wang, H.; Yusa, S.; Weiss, T.C.; Romanjuk, P.J.; Pickerill, S.; You, Q. Cross priming amplification: Mechanism and optimization for isothermal DNA amplification. *Sci. Rep.* 2012, 2, 246. [CrossRef] [PubMed]

95. Ren, X.; Li, P. Development of reverse transcription loop-mediated isothermal amplification for rapid detection of porcine epidemic diarrhea virus. *Virus Genes 2011*, 42, 229–235. [CrossRef] [PubMed]

96. Kim, J.K.; Kim, H.R.; Kim, D.Y.; Kim, J.M.; Kwon, N.Y.; Park, J.H.; Park, J.Y.; Kim, S.H.; Lee, K.K.; Lee, C.; et al. A simple colorimetric detection of porcine epidemic diarrhea virus by reverse transcription loop-mediated isothermal amplification assay using hydroxynaphtol blue metal indicator. *J. Virol. Methods*. 2021, 298, 114289. [CrossRef]
97. Yu, X.; Shi, L.; Lv, X.; Yao, W.; Cao, M.; Yu, H.; Wang, X.; Zheng, S. Development of a real-time reverse transcription loop-mediated isothermal amplification method for the rapid detection of porcine epidemic diarrhea virus. Virol. J. 2015, 12, 76. [CrossRef]
98. Mai, T.N.; Nguyen, V.D.; Yamazaki, W.; Okabayashi, T.; Mitoma, S.; Notsu, K.; Sakai, Y.; Yamaguchi, R.; Norimine, J.; Sekiguchi, S. Development of pooled testing system for porcine epidemic diarrhea using real-time fluorescent reverse-transcription loop-mediated isothermal amplification assay. BMC Vet. Res. 2018, 14, 172. [CrossRef]
99. Gou, H.; Deng, J.; Wang, J.; Pei, J.; Liu, W.; Zhao, M.; Chen, J. Rapid and sensitive detection of porcine epidemic diarrhea virus by reverse transcription loop-mediated isothermal amplification combined with a vertical flow visualization strip. Mol. Cell. Probes. 2015, 29, 48–53. [CrossRef]
100. Zhou, L.; Chen, Y.; Fang, X.; Liu, Y.; Du, M.; Lu, X.; Li, Q.; Sun, Y.; Ma, J.; Lan, T. Microfluidic-RT-LAMP chip for the point-of-care detection of emerging and re-emerging enteric coronaviruses in swine. Anal. Chim. Acta 2020, 1125, 57–65. [CrossRef]
101. Madou, M.; Zoval, J.; Jia, G.; Kido, H.; Kim, J.; Kim, N. Lab on a CD. Annu. Rev. Biomed. Eng. 2006, 8, 601–628. [CrossRef] [PubMed]
102. Gorkin, R.; Park, J.; Siegrist, J.; Amasia, M.; Lee, B.S.; Park, J.M.; Kim, J.; Kim, H.; Madou, M.; Cho, Y.K. Centrifugal microfluidics for biomedical applications. Lab Chip 2010, 10, 1758–1773. [CrossRef] [PubMed]
103. Antas, M.; Olech, M.; Szczotka-Bochniarz, A. Molecular characterization of porcine epidemic diarrhoea virus (PEDV) in Poland reveals the presence of swine enteric coronavirus (SeCoV) sequence in S gene. PLoS ONE 2021, 16, e0258318. [CrossRef] [PubMed]
104. Zhang, H.; Han, F.; Yan, X.; Liu, L.; Shu, X.; Hu, H. Prevalence and phylogenetic analysis of spike gene of porcine epidemic diarrhea virus in Henan province, China in 2015–2019. Infect. Genet. Evol. 2021, 88, 104709. [CrossRef] [PubMed]
105. Than, V.T.; Choe, S.E.; Vu, T.T.H.; Do, T.D.; Nguyen, T.L.; Bui, T.T.N.; Mai, T.N.; Cha, R.M.; Song, D.; An, D.J.; et al. Genetic characterization of the spike gene of porcine epidemic diarrhea virus (PEDVs) circulating in Vietnam from 2015 to 2016. Vet. Med. Sci. 2020, 6, 535–542. [CrossRef]
106. Kim, S.J.; Nguyen, V.G.; Huynh, T.M.; Park, Y.H.; Park, B.K.; Chung, H.C. Molecular Characterization of Porcine Epidemic Diarrhea Virus and Its New Genetic Classification Based on the Nucleocapsid Gene. Viruses 2020, 12, 790. [CrossRef]
107. Dong, B.; Dai, A.; Li, X.; Yang, X. The four of structural genes sequences of a porcine epidemic diarrhea virus from domestic piglet in Fujian, China. Virol. J. 2020, 17, 79. [CrossRef]
108. Sun, P.; Gu, C.Y.; Ding, Y.Y.; Wei, J.H.; Yin, Z.J.; Geng, Z.Y.; Li, Y. Sequence and phylogenetic analyses of the M and N genes of porcine epidemic diarrhea virus (PEDV) strains in Anhui Province, China. Genet. Mol. Res. 2015, 14, 13403–13413. [CrossRef]
109. Chen, J.F.; Sun, D.B.; Wang, C.B.; Shi, H.Y.; Cui, X.C.; Liu, S.W.; Qiu, H.J.; Feng, L. Molecular characterization and phylogenetic analysis of membrane protein genes of porcine epidemic diarrhea virus isolates in China. Virus Genes 2008, 6, 355–364. [CrossRef]
110. Sun, R.; Leng, Z.; Zhai, S.L.; Chen, D.; Song, C. Genetic variability and phylogeny of current Chinese porcine epidemic diarrhea virus strains based on spike, ORF3, and membrane genes. Sci. World J. 2014, 2014, 208439. [CrossRef]
111. Crossley, B.M.; Bai, J.; Glaser, A.; Maes, R.; Porter, E.; Killian, M.L.; Clement, T.; Toohey-Kurth, K. Guidelines for Sanger sequencing and molecular assay monitoring. J. Vet. Diagn. Invest. 2020, 32, 767–775. [CrossRef] [PubMed]
112. Boniotti, M.B.; Papetti, A.; Lavazza, A.; Alborali, G.; Sozzi, E.; Chiapponi, C.; Faccini, S.; Bonilauri, P.; Cordioli, P.; Marthaler, D. Porcine Epidemic Diarrhea Virus and Discovery of a Recombinant Swine Enteric Coronavirus, Italy. Emerg. Infect. Dis. 2016, 22, 83–87. [CrossRef]
113. García-Hernández, M.E.; Trujillo-Ortega, M.E.; Akaraz-Estrada, S.L.; Lozano-Aguirre-Beltrán, L.; Sandoval-Jaime, C.; Taboada-Ramírez, B.I.; Sarmiento-Silva, R.E. Molecular Detection and Characterization of Porcine Epidemic Diarrhea Virus and Porcine Aichivirus C Coinfection in Mexico. Viruses 2020, 12, 305. [CrossRef] [PubMed]
114. Cassidy, A.; Farle-McDermott, A.; O’Kennedy, R. Virus Detection: A Review of the Current and Emerging Molecular and Immunological Methods. Front. Mol. Biosci. 2021, 8, 637559. [CrossRef] [PubMed]
115. Yang, K.; Liang, Y.; Li, Y.; Liu, Q.; Zhang, W.; Yin, D.; Song, X.; Shao, Y.; Tu, J.; Qi, K. Reverse transcription-enzymatic recombinase amplification coupled with CRISPR-Cas12a for rapid detection and differentiation of PEDV wild-type strains and attenuated vaccine strains. Anal. Bioanal. Chem. 2018, 413, 7521–7529. [CrossRef]
116. Liu, J.; Tao, D.; Chen, X.; Shen, L.; Zhu, L.; Xu, B.; Liu, H.; Zhao, S.; Li, X.; Liu, X.; et al. Detection of Four Porcine Enteric Coronaviruses Using CRISPR-Cas12a Combined with Multiplex Reverse Transcriptase Loop-Mediated Isothermal Amplification Assay. Viruses 2022, 14, 833. [CrossRef]